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ABSTRACT
Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease leading 
to progressive muscle wasting and paralysis and premature death. The disease is 
predominantly sporadic (sALS) in nature with approximately 10% of case inherited 
(familial ALS). In the present study, I have examined the subcellular distribution and 
expression of the AMPA receptor subunits and the proteins involved in their trafficking 
between the cytosol and postsynaptic membrane (ABP, PICK1 and NSF) in a mouse 
model of familial ALS (SOD1G93A mice) at different stages of the disease.
The main finding was a decrease of GluR2 AMPA receptor subunit selectively in 
cytosol, but not in synaptic membrane of spinal motor neurons of SOD1G93A mice 
before symptoms onset. This suggests that an impairment in the usually well-organized 
trafficking of the GluR2 AMPA is likely the cause of the increased degradation of this 
receptor subunit. In support of this, increased level of the trafficking protein NSF, able 
to increase the delivery of GluR2 at the cell surface, was reported selectively in the 
motor neurons at the presymptomatic stage of the disease in SOD1G93A mice.
Since GluR2 plays an important role in regulating the calcium entrance in the cells by 
the AMPA receptors, I hypothesise that the increase of NSF may be an attempt to 
protect motor neurons from excitotoxicity by maintaining the sufficient levels of GluR2 
subunit in the membrane. However, since an overall degradation of this subunit occurs 
in the motor neurons, this effect is probably no longer efficacious.
At symptomatic and end stage of the disease increased immunoreactivity of GluRl, 2 
and 3 AMPA receptor subunits was found in the activated glial cells. Although there are
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evidences of a role of reactive glia in favouring the neuronal excitotoxicity, the 
relevance of this effect needs to be investigated.
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CHAPTER 1 
GENERAL INTRODUCTION
1.1 CLASSIFICATION OF MOTOR NEURON 
DISORDERS
The motor neuron diseases (MND) are a group of progressive neurological 
disorders that destroy motor neurons, the cells that control voluntary muscle 
activity. Different MND have been classified so far that comprises disorders of 
lower or the upper motor neurons, called spinal muscular atrophy, progressive 
muscular atrophy, progressive and primary lateral sclerosis, and amyotrophic 
lateral sclerosis.
1.1.1 Spinal Muscular Atrophy (SMA):
Is a term applied to a number of different disorders, all having in common a 
genetic cause and the manifestation of weakness due to loss of the motor 
neurons of the spinal cord and brainstem. The most common form of SMA is 
caused by mutation of the SMN (Survival Motor Neuron) gene. There are two 
copies of the gene SMN, SMN1 and SMN2. SMA is caused by loss of the 
SMN1 gene from both chromosomes (Monani et al, 2005). SMA manifests over 
a wide range of severity affecting infants through adults. The spectrum of 
severity of SMA has been divided arbitrarily into three groups by the level of 
weakness and is partly related to how well the remaining SMN2 genes can 
compensate for the loss of SMN1.
• Infantile SMA - Type 1 or Werdnig-Hoffmann disease (generally 0-6 
months). SMA type 1, also known as severe infantile SMA or Werdnig
Hoffmann disease, is the most severe, and manifests in the first year of life with 
the inability to ever maintain an independent sitting position.
• Intermediate SMA - Type 2 (generally 7-18 months). Type 2 SMA, or 
intermediate SMA, describes those children who are never able to stand and 
walk, but who are able to maintain a sitting position at least some time in their 
life. The onset of weakness is usually recognized some time between 6 and 18 
months.
• Juvenile SMA - Type 3 or Kugelberg-Welander disease (generally 
>18 months). SMA type 3 describes those who are able to walk at some time. It 
is also known as Kugelberg Welander disease.
1.1.2 Progressive bulbar palsy
It is a form of motor neuron disease characterized by dysfunction of the muscles 
controlled by the cranial nerves of the lower brain stem specifically, the 
glossopharyngeal nerve (EX), vagus nerve (X), and hypoglossal nerve (XII).
1.1.3 Primary Lateral Sclerosis (PLS)
It is a rare neuromuscular disease characterized by progressive muscle weakness 
in the voluntary muscles. Onset of PLS usually occurs after age 50. Symptoms 
may include difficulty with balance, weakness and stiffness in the legs, and 
clumsiness. Other symptoms may include spasticity (sudden, involuntary 
muscle spasms) in the hands, feet, or legs; foot dragging, and speech problems 
due to involvement of the facial muscles. The disorder usually begins in the 
legs, but it may also start in the tongue or the hands.
The disease, not hereditary, progresses gradually over a number of years, or 
even decades. In PLS, there is no evidence of the degeneration of spinal motor 
neurons or muscle wasting (amyotrophy) that occurs in amyotrophic lateral 
sclerosis, which it resembles. Diagnosis of PLS is often delayed because it is 
mistaken for ALS.
1.1.4 Amyotrophic Lateral Scerosis (ALS)
ALS is the most common among MND. J. M. Charcot in 1874 first described 
the clinical and neuropathological features of ALS among a heterogeneous 
group of MND. The origin of the term “ALS” arises from the post mortem 
pathological analysis of patients describing the loss of muscular mass 
(amyotrophic) associated with the hardening (sclerosis) of the lateral columns of 
the spinal cord. So far, an early diagnosis of the pathology by a specific marker 
is not possible and the following clinical signs are the only way to diagnose 
ALS pathology:
18
1.2 DIAGNOSIS OF THE AMYOTROPHIC
LATERAL SCLEROSIS
ALS is a devastating disease affecting the upper and lower motor neurons which 
leads to a progressive muscular weakness until a complete motor paralysis and 
death within 3-5 years from the diagnosis. So far, an early diagnosis of the 
pathology by a specific marker is not possible and the clinical signs are the only 
mode to diagnose ALS pathology. The requirements for diagnosis of ALS were 
defined by the El Escorial criteria in 1994 and subsequently revised in order to 
increase their sensitivity by a workshop convened at Airlie Conference Center, 
Warrenton, Virginia on April 2-4, 1998 by the World Federation of Neurology 
Research Committee on Motor Neuron Diseases.
According to these criteria the diagnosis of ALS requires the presence
of:
-signs of lower motor neuron (LMN) degeneration by clinical, 
electrophysiological or neuropathologic examination
-evidence of upper motor neuron (UMN) degeneration by clinical examination.
-progressive spread o f symptoms or signs within a region or to other regions, as 
determined by history or examination,
together with the absence of:
-electrophysiological and pathological evidence o f other disease processes that 
might explain the signs of LMN and/or UMN degeneration, and
- neuroimaging evidence o f other disease processes that might explain the 
observed clinical and electrophysiological signs.
A careful physical and neurological examination must search for clinical 
evidence of UMN and LMN signs (Table 1.0) in four regions (brainstem, 
cervical, thoracic or lumbosacral spinal cord) of the central nervous system 
(CNS). Tests should be applied, as clinically indicated, to exclude other disease 
processes. These should include electrodiagnostic, neurophysiological, 
neuroimaging and clinical laboratory studies. The clinical diagnosis of ALS, 
without pathological confirmation, may be categorized into various levels of 
certainty.
According to clinical criteria it is possible to define four diagnostic categories: 
Definite ALS
It is defined on clinical evidence alone by the presence of UMN, as well as 
LMN signs, in the bulbar region and at least two of the other spinal regions 
(cervical, thoracic and lumbosacral).
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Probable ALS
It is defined on clinical evidence alone by the presence of UMN and LMN signs 
in at least two regions with some UMN signs necessarily rostral to the LMN 
signs.
Probable - Laboratory-supported ALS
It is defined when clinical signs of UMN and LMN dysfunction are in only one 
region, or when UMN signs alone are present in one region, and LMN signs 
defined by EMG criteria are present in at least two limbs, with proper 
application of neuroimaging and clinical laboratory protocols to exclude other 
causes.
Possible ALS
It is defined when clinical signs of UMN and LMN dysfunction are found in 
only one region or UMN signs alone are found in two or more regions; or LMN 
signs are rostral to UMN signs
Suspected ALS
It manifests only with LMN signs in two or more regions which is typical also 
of the progressive muscular atrophy. Therefore, this category has been deleted 
from the revised El Escorial Criteria for the diagnosis of ALS
21
Lower motor Upper motor
neurons neurons
Symptoms
Fatigue Weakness
Weakness Incoordination
Cramps Stiffness
Twitching of Slowing of
muscles distal
Incoordination movement
Weakness Spasticity
Signs Fasciculations Brisk reflexes
Suppression Babinski and
of reflexes Hoffman
Hypotonia signs
Atrophy Weakness
Pseudobulbar
effect
Table 1.0: Lower and upper motor neuron dysfunctions in ALS
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1.3 CLINICAL PHENOTYPE OF AMYOTROPHIC
LATERAL SCLEROSIS
Amyotrophic lateral sclerosis is characterized by a sequence of symptoms and 
rate progression that varies from person to person. The degeneration of the 
UMNs lead to development of symptoms represented by muscle weakness, 
spasticity, and hyperreflexia; while the loss of LMNs determines the muscle 
weakness, atrophy, fasciculations, hypotonia, and areflexia. Since ALS affects 
only motor neurons, the senses of sight, touch, hearing, taste and smell, muscles 
of the eyes and bladder are generally not affected.
The initial symptoms of the disease are so slight that they are frequently 
overlooked and can be quite variable in different people. Also the rate of disease 
progression can be quite variable from one patient to another. With regard to the 
appearance of symptoms and the progression of the illness, the course of the 
disease may include the following:
• muscle weakness in one or more of the following: hands, arms, legs 
or the muscles of speech, swallowing or breathing
• twitching (fasciculation) and cramping of muscles, especially those
in the hands and feet
• impairment of the use of the arms and legs
• 'thick speech' and difficulty in projecting the voice
• in more advanced stages, shortness of breath, difficulty in breathing
and swallowing
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ALS symptoms may be related to either limb onset, bulbar onset or both.
Limb onset affects the extremities and torso. A general weakness of one or more 
legs, arms and hands and fatigue may be the first sign of the disease. Muscle 
cramping and fasciculations (muscle twitching) will begin to develop. As the 
disease progresses, the patient may stumble while walking or loose grip of 
objects. Breathing may become laboured. Uncontrolled crying and/or laughing 
(pseudobulbar affect) can occur.
Bulbar onset affects the face, mouth and throat muscles. With bulbar onset, 
one's voice may begin to weaken and become slurred. Chewing and swallowing 
becomes difficult (dysphagia). Fasciculations will develop in the tongue. Limb 
onset cases will eventually develop bulbar symptoms.
Muscle weakness is a hallmark initial sign in ALS, occurring in approximately 
60% of patients. Early symptoms vary with each individual, but usually include 
tripping, dropping things, abnormal fatigue of the arms and/or legs, slurred 
speech, muscle cramps and twitches and/or uncontrollable periods of laughing 
or crying. The hands and feet may be affected first, causing difficulty in lifting, 
walking or using the hands for the activities of daily living such as dressing, 
washing and buttoning clothes. As the weakening and paralysis continue to 
spread to the muscles of the trunk of the body, the disease eventually affects 
speech, swallowing, chewing and breathing. When the breathing muscles 
become affected, the patient will need permanent ventilation support in order to
survive.
The progression rate scale of the pathology is based on two rating scale:
ALS Functional Rating Scale: Developed by the WFN (World Federation of 
Neurology) in 1996, the ALS Functional Rating Scale is a scorecard for 
assessing a patient’s condition by looking at aspects such as swallowing, 
speaking, movement, etc. The score range is composed from 0 to 48, with 48 
being normal and 0 being unable to perform.
Appel ALS Rating Scale: Based on much of the same aspects as the scale 
created by WFN. The AALS was developed at Baylor College of Medicine to 
provide a reliable, quantitative estimate of the functional impairment and 
symptom progression of patients with ALS (Appel et al., 1987; Haverkamp et 
al., 1995). It includes subjectively and objectively quantified assessments of:
-bulbar function (speech and swallowing)
-respiratory function 
-muscle strength in arms and legs 
-upper extremity function 
-lower extremity function
The AALS total score is the sum of all 5 assessments and covers a broad range 
of disability. One important feature of this rating scale is that it provides a single 
quantitative index of clinical status that documents the variable manifestation 
and progression of ALS and predicts survival time in patients.
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1.4 NEUROPATHOLOGY OF ALS
Combined upper motor neuron (UMN) and lower motor neuron (LMN) signs 
are involved in ALS and manifested by degenerative changes in the motor 
system. These changes have been documented since the studies of Charcot in
tVithe mid 19 century that revealed:
a reduction in both the number and size of lower motor neurons 
in the ventral horns and in the bulbar motor nuclei 
myelin pallor in the corticospinal projection pathway (axonal loss 
degeneration)
upper motor neuron soma alteration (much more variable)
1.4.1 Degeneration of Upper Motor Neuron (UMN)
There is variability in the autopsy of ALS about the neuropathological 
alterations of the UMN. The most severely affected cases showed a loss of the 
giant Betz cells in cortical layer (5° stratum) with an increased astrocytosis and 
microgliosis. However, it is not easy to determine a loss of UMN because there 
is no molecular marker that exclusively labels UMN. Furthermore, UMN 
degeneration leads to shrinkage of the cells so that Betz cells become 
indistinguishable from others cells in the cortical layers. Also, pallor of the 
corticospinal tract has been demonstrated in ALS patients as a consequence of 
the UMN degeneration. However, a different hypothesis suggests that the
axonopathy may be due to the dying back degeneration of the UMN axons 
rather that initial UMN cell bodies degeneration.
1.4.2 Degeneration of Lower Motor Neuron (LMN)
A selective loss of motor neurons in the spinal cord occurs in ALS. However, 
not all lower motor neurons undergo neurodegeneration. Two groups are spared 
in most cases: the sacral motor nucleus of Onufrowitz (Onufs nucleus) which 
innervates muscles of the pelvic floor; and are responsible for maintaining 
retention of urinary and faecal continence, and the motor neurons that innervate 
the external ocular muscles (third, fourth and sixth cranial nerves) and preserve 
normal eye movement. The selective sparing of these groups of motor neurons 
is likely due to physiological and biological properties of these cells such as the 
increased amount of calcium buffering protein, the lack of direct monosynaptic 
corticospinal innervation, glutamatergic neurotransmission or nitric oxide 
metabolism.
1.4.3 Non-motor neuron pathology in ALS
In some cases of ALS, other CNS structures can be partially involved during the 
progression of the pathology. The extra motor neuron structures involved are 
the sensory system, cerebellar pathways and substantia nigra.
At autopsy pallor of the dorsal funiculi (dorsal root entry zone in the funiculus 
cuneatus and in the funiculus graciles) of the spinal cord which belong to the 
sensory system was observed in familial ALS cases. However, a degeneration of
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the sensitive neurons was not present in ALS cases. Sporadically, it has been 
also observed that atrophy occurs in the posterior root ganglia, peripheral 
sensory nerve and thalamic gliosis.
Also frequent myelin pallor in the lateral and ventral white matter has been 
revealed in ALS patients, representing a compromised ascending 
spinocerebellar tract pathway during the progression of the disease. A 
subclinical Parkinsonism (no clear evidences of a Lewy body degeneration), 
developed from a degeneration of dopaminergic neuron in the substantia nigra, 
was present in some cases of ALS patients (Burrow and Blumbergs, 1992; Kato 
etal., 1993).
1.4.4 Non-CNS pathology in ALS
A direct consequence of the degeneration of the motor neuron is a skeletal 
muscle atrophy characterized by fibres clustering derived from serial 
denervation and reinervation of the muscle. The phenomenon of sprouting is 
also evident as a tendency to restore the muscle innervation (Wohlfart, 1957). 
Other tissues are involved during the progression of the disease, such as changes 
in collagen cross-linking or in the proportion of immature collagen, and rapid 
degeneration of the elastin component (Ono and Yamauchi, 1994).
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1.5 MOLECULAR PATHOLOGY
The ALS pathology determines a series of abnormalities in the cytoplasm of 
motor neurons and glial cells which are represented by intracellular inclusion in 
the anterior horn cells and in other neuronal populations. Most of these 
inclusions are specific for ALS but some are shared with other 
neurodegenerative diseases, such as neurofibrillary tangles in motor neurons in 
patients with the ALS-Parkinson’s disease dementia complex of GUAM.
The most specific features of the ALS neuropathology at the autopsy tissues 
analysis from patients are represented by:
• Ubiquitin inclusion
• Bunina Bodies
• Hyaline conglomerate inclusions
• Golgi apparatus alterations
• Globules and spheroids
1.5.1 Ubiquitinated Bodies Inclusions (UBI)
Tissues autopsy of ALS patients revealed skein-like inclusions or Lewy body­
like accumulation of ubiquitinated substrates in the LMN. These inclusions 
occur specifically in the nervous system of ALS patients and are very infrequent 
in patients with other types of neurodegeneration. Furthermore, the motor
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neurons spared in ALS (the oculomotor nuclei and Onuf s nucleus) did not 
usually show ubiquitin inclusion.
These deposits were evident in the normal appearing neurons and in 
morphologically altered neurons, demonstrating there is no direct correlation 
between the presence of the inclusion bodies and the degeneration event. 
Ubiquitin protein is a 76 aminoacid protein distributed in all cells of the 
organism. The main role of this protein is to tag abnormal peptides that 
subsequently will be eliminated by an extra-lysosomal alternative energy 
dependent pathway of degradation that involves several enzymes: ubiquitin 
proteasome pathway (Hershko et al., 1980). Ubiquitin proteasome system or 
ubiquitin-26S proteasome system is a barrel-shaped multi-protein complex that 
specifically is able to degrade unwanted and misfolded proteins into short 
polypeptides and amino acids in an ATP-driven reaction. Several enzymes in 
cascade regulate this process: El ubiquitin activating, E2 ubiquitin conjugating, 
and E3 ubiquitin ligase enzymes. Through these enzymes the ubiquitin 
monomers are attached sequentially to target proteins. The polyubiquitinated 
proteins are then recognized by the 26S proteasome, a large ATP-dependent 
multicatalytic protease, which removes the ubiquitin chain and degrades the 
proteins to short peptides. The selection and specific timing of 
polyubiquitination of the target proteins are conferred by different E3 ubiquitin 
ligases. As well as degrading misfolded proteins, the proteasome is involved in 
destruction of proteins that are regulated temporally (e.g. cell cycle regulators), 
or by environmental factors (e.g. cholesterol synthesis regulators and several 
transcription factors). Furthermore, ubiquitin is involved in cell stress responses 
and is also a heat shock protein involved in several insults to the cells (Bond and 
Schlesinger, 1985). The ubiquitin inclusions are also characterized by the
presence of the filaments and tubules of 15-25 nm in diameter (Lowe et al., 
1988; Murayama et al., 1989; Murayama et al., 1990; Mizusawa et al., 1991; 
Schiffer et al., 1991) and smaller filaments of 10-15 nm in diameter. These 
inclusions do not show deposits of tau, a-synuclein and neurofilaments such as 
revealed in other neuropathology. UBIs are thought to result from the 
breakdown of abnormal proteins caused by oxidative stress, implicated in the 
pathogenesis of ALS (Alves-Rodrigues et al., 1998). This lesion characterized at 
least 80-100% of sporadic cases.
The ubiquitinated inclusions found in ALS have been classified as skein-like 
and Lewy body-like inclusions. Skein-like inclusions are a specific hallmark of 
ALS, whereas Lewy body-like inclusions are not so specific for ALS. Both the 
inclusions probably represent two different morphological stages of protein 
aggregations, from diffuse filamentous forms to dense and compact inclusions. 
In skein-like arrays, ubiquitin labelling is concentrated on abnormally formed 
15-20 nm filaments and on neurofilament immunostaining localized on 10 nm 
filaments adjacent to or in continuity with the abnormal filaments (Migheli et 
al., 1994). Besides phosphorylated neurofilaments and ubiquitin, Lewy body­
like inclusions also contain CDK5 kinase, a cycline-dependent kinase 
(Nakamura et al., 1997). Moreover, in inclusion bodies found in the motor 
neurons and neuronal processes of familial and sporadic ALS, has been revealed 
dorfin, a RING finger-type E3 ubiquitin ligase, (Hishikawa et al., 2003) and 
activated p38MAPK (Bendotti et al., 2004), an intracellular signalling kinase 
involved in stress stimulus and inflammatory events.
The tissue of ALS showed both skein-like inclusion and Lewy body-like 
ubiquitin inclusion, with a predominance of one type in some cases.
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1.5.2 Bunina bodies (BBs)
BBs, which are cystatin C-containing inclusions, are found in the cell bodies of 
motor neurons in ALS (Okamoto et al., 1993; Sasaki and Maruyama, 1994). 
They are represented by small eosinophilic bodies composed by lysosomal 
material and they have been described in 30-50% of sporadic and familial ALS 
patients. However, they are now thought to be less specific for ALS than the 
ubiquitinated and neurofilamentous inclusions.
1.5.3 Hyaline conglomerate inclusions
These inclusions found in the spinal cord of ALS patients, are less specific for 
this neuropathology, as they have been also described in normal subjects and in 
other neurological diseases (Leigh et al., 1989; Sobue et al., 1990) although at a 
lower frequency. These inclusions are composed by aggregates of 
phosphorylated and non phosphorylated neurofilaments of 10-15 nm that are 
able to entrap other proteins and organelles (Hirano et al., 1967; Carpenter, 
1968; Schochet et al., 1969; Kondo et al., 1986; Sasaki et al., 1988; Mizusawa 
et al., 1989). However, these aggregates were much less common than UBIs.
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1.5.4 Fragmented Golgi apparatus (GA)
The GA is a crucial component of the cell, because it is involved in the transport 
and processing of polypeptides as well as in their targeting to different 
destinations, such as plasma membranes and lysosomes (Farquhar and Palade, 
1981; Farquhar, 1985). Several studies revealed that the GA of the anterior horn 
cells is fragmented in sporadic (Kato et al., 1987; Gonatas et al., 1992; 
Matsumoto et al., 1996; Gonatas et al., 1998; Fujita et al., 1999; Fujita et al., 
2002) and familial ALS patients (Fujita et al., 2000). This lesion of the GA 
consists of the dispersion of the normal network of the organelle into numerous 
small disconnected elements suggesting that the organelle is fragmented. 
Furthermore, fragmented GA, with an identical pattern to that observed in 
patients with ALS, was revealed in asymptomatic transgenic mice expressing 
G93 A mutation before the onset of paralysis, suggesting that this alteration is an 
early and specific target of the pathological process (Mourelatos et al., 1996). 
These studies suggested that fragmentation of a structure with such crucial roles 
in the cellular handling of proteins was likely to be associated with significant 
impairment of function, revealing another possible early target for the motor 
neuron degeneration.
1.5.5 Globules and spheroids
Another important alteration revealed in the autopsy of ALS patients is the 
axonal swellings in the anterior horn. This is due to disoriented conglomeration 
of phosphorylated neurofilaments called spheroids and globules. Spheroids tend
to be in proximal axons, while globules are present much more distal in the 
ventral horn (Sobue et al., 1990). Some spheroids may be also in dendrites 
(Sasaki et al., 1988). A deregulated anterograde transport of neurofilaments was 
hypothesized with this alteration.
1.6 GENETICS OF ALS
The studies of Charcot on 20 ALS patients in the 1860s suggested that ALS 
pathology was not a hereditary disease. Subsequently, this view was challenged 
by other authors demonstrating an inheritance pattern of the disease (Kurland 
and Mulder, 1955; Cudkowicz et al., 1997). Other studies confirmed that the 
familial form of ALS (FALS) can be inherited as an autosomal trait (9-10%). 
The clinical features of sporadic and familial ALS are not distinguishable 
although FALS shows an earlier onset which is more pronounced at the lower 
extremities (Mulder et al., 1986).
An important contribution on the pathogenesis of ALS was made by Rosen and 
colleagues. In 1993 this group reported that some FALS families are genetically 
linked to chromosome 2 lq22.1-22.2 and the gene involved was the SOD1 
(Rosen et al., 1993). SOD1 is a cytoplasmic homodimeric enzyme ubiquitously 
distributed in eukaryotic cells which is coded by five exons and each subunit 
consists of 153 amino acids. In the nervous system it represents 2% of the 
proteins. Its functions consist in the catalysis of free radical superoxide, 
generated mainly from the oxidative phosphorylation in the mitochondria, to 
hydrogen peroxide and oxygen mediated by copper (Fig 1.0).
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Fig 1.0: SOD1 chemistry
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It was initially proposed that the toxicity of mutated SOD1 is associated with 
the loss of superoxide dismutase activity. However, most mutated SOD1 forms 
appear to fully retain their enzymatic property. The creation of transgenic mice 
expressing SOD1 with some of the mutations found in the human patients, 
which develop a motor syndrome similar to human ALS, shows that catalytic 
activity is unchanged or elevated (Gurney et al., 1994; Ripps et al., 1995). 
Furthermore, SOD1 knockout mice do not develop spontaneous motor neuron 
disease (Reaume et al., 1996; Wong et al., 1995; Bruijn et al., 1997b). The 
conclusion is that SOD1 mutants acquire one or more toxic properties, 
irrespective of the amount of superoxide dismutase activity that each of them 
retains.
So far more than one hundred different mutations have been revealed in the 
Cu/Zn-SOD-1 gene of FALS patients. Almost all the mutations are dominant 
missense mutations (an aminoacid substitution), except for SOD1D90A
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mutation that has a recessive trait. However, the variability of the gene mutation 
does not determine a distinguishable clinical phenotype.
Recently another 2 genes have been shown to be involved in recessive 
inheritance and juvenile ALS form. One genetic alteration was revealed in 7 
Tunisian families with a mutation locus localized in 15ql5.22, but the gene has 
not been identified so far. The second gene is mapped to chromosome 2q33 that 
encodes a 184 Kda protein derived from 34 exons that span 80Kb and showed 
deletion mutations (Yang et al., 2001). This gene, called ALS2 or Alsin, is 
widely expressed and contains an amino acid sequence in the amino-terminal 
that belongs to guanine exchange factors (GEFs) that are involved in the 
exchange from the GDP bound state to the GTP state in a small G protein. The 
carboxy-terminal contains a domain characteristic of the Rho G-protein family, 
which is able to modulate dynamic actin assembly.
Other gene mutations that are rarely causative in ALS include deletions or 
insertions in the neurofilament genes. In fact, alterations in the NF heavy 
subunits genes in the lysine-serine-proline (KSP) motifs were identified in a 
small percentage of ALS patients (1% of 1300 sporadic ALS patients) (Al- 
Chalabi et al., 1999). Other gene alterations were revelead such as mutations in 
mitochondrial DNA encoded subunit I of cytochrome C oxidase (Borthwick et 
al., 1999) or abnormal SMN1 (Survival Motor Neuron 1) gene copy number 
(Corcia et al., 2002) and NAIP (Neuronal Apoptosis Inhibitor Protein) 
mutations (Jackson et al., 1996). These latter two genes are mainly involved in 
the survival of motor neurons. Furthermore, variant mRNA transcripts for the 
astroglial glutamate transporter exciatory amino acid transporter (EAAT2 in 
human or GLT-1 in mouse) were showed in the central nervous system of 
sporadic ALS (SALS) patients (Lin et al., 1998). Other loci mapped, to
chromosome 9q34 were identified in a juvenile form of ALS characterized by a 
very slow progression of distal limb atrophy and motor neuron loss that does not 
reduce the life span (Chance et al., 1998). The gene involved in these mutations, 
Senataxin gene, encodes for a protein that contain a DNA/RNA helicase domain 
with strong homology to genes such as human RENT1 and IGHMBP2, which 
encode proteins involved in RNA processing (Chen et al., 2004). A 
debrisoquine hydroxylase gene polymorphism was also described in patients 
with ALS (Siddons et al., 1996). This encodes for a cytochrome P450 
monooxigenase protein involved in drug metabolism and associated with a poor 
metabolism phenotype. Furthermore, a novel missense mutation in the vesicle- 
associated membrane protein/synaptobrevin-associated membrane protein B 
(VAPB) gene was reported in ALS patients (Nishimura et al., 2004). Vesicle- 
associated proteins are intracellular membrane proteins that are associated with 
microtubules and have a function in membrane transport (Nishimura et al., 
2004).
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1.7 ANIMAL MODELS OF AMYOTROPHIC
LATERAL SCLEROSIS
The discovery of the SOD1 mutant gene by Rosen et al. (Rosen et al., 1993) as 
the cause of a subgroup of FALS has lead to the generation of transgenic mice 
carrying the human SOD1 gene with different mutations. These mice develop a 
phenotype similar in many aspects to human ALS pathology. Different lines of 
transgenic mice overexpressing human mutant SOD1 (SOD1G93A, 
SOD1G37R and SOD1G85R) or mouse mutant SOD1 (SOD1G86R) have been 
produced. More recently rat models with SOD1G93A and SOD1H46R have 
also been developed (Nagai et al., 2001). SOD1G93A mice are the most used 
animal models as they have been commercially available for a long time.
All these animals develop a motor syndrome characterized by selective motor 
neuron death. They show normal motor functions in the early phase of their life 
but then develop a progressive weakness, especially starting in the hind limbs, 
which eventually results in paralysis and death. The age of onset, the duration 
and several pathological features of this motor dysfunction show some 
differences in the transgenic animals’ strains. However, all these transgenic 
mice and rats provide an excellent and suitable in vivo model resembling human 
ALS.
Mice expressing SOD1G85R develop a late onset but very aggressive 
pathology (2 weeks from the first symptoms to the death), even with a low 
expression of the transgene. Motor neurons and astrocytes present inclusions 
immunopositive for ubiquitin and SOD1 (Bruijn et al., 1997b).
Transgenic mice expressing low level of SOD1G37R mutant shows a motor 
disease restricted to LMN, whereas higher copy number causes more severe
abnormalities and affect a variety of other neuronal populations. The most 
obvious cellular abnormality is the presence in axons and dendrites of 
membrane-bounded vacuoles, which appear to be derived from degenerating 
mitochondria (Wong et al., 1995).
Transgenic mice that express mutant SOD1G93A develop motor system disease 
mainly affecting motor neurons. Ultrastructural and microscopical analysis 
reveals that the earliest pathological feature in these mice is vacuolization of 
large neurons of the anterior horns of the spinal cord (Bendotti et al., 2001a). At 
the end stage, motor neuronal depletion is evident and hyaline filamentous 
inclusions immunopositive for ubiquitin and neurofilaments are present in some 
of the surviving neurons (Gurney et al., 1994; Migheli et al., 1994).
It is noteworthy that transgenic mice overexpressing the wild type form of 
human SOD1 (SOD1WT) do not develop any motor symptoms or altered 
phenotype. However, some neurodegenerative changes consisting of swelling 
and vacuolization of mitochondria, axonal degeneration of some long fiber 
tracts and a moderate loss of spinal motor neurons at two years of age, were 
reported (Jaarsma et al., 2000). Thus, SOD1WT transgenic mice have 
demonstrated that mutations on SOD1 gene are necessary to induce an evident 
motor disease. Therefore, transgenic technology has directly clarified that SOD1 
mutants cause pathology because of gain of function and not because of the loss 
of SOD1 catalytic properties. Moreover, expression of mutant forms of SOD1 
restricted to astrocytes or neurons is not sufficient to cause motor neuron 
degeneration in transgenic mice (Gong et al., 2000; Pramatarova et al., 2001; 
Lino et al., 2002). These reports suggest that simultaneous alterations in both 
neuronal and astroglial cells are necessary to induce the pathology in ALS mice.
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More recently, the transgenic technology has also permitted the creation of 
transgenic rats expressing the G93A mutant of SOD1. Motor neuron disease in 
these animals depends on high levels of mutant SOD1 expression. Disease onset 
in SOD1G93A rats is quite early and disease progression is very rapid (11 days 
to reach the end stage). Pathological abnormalities include vacuoles initially in 
the lumbar spinal cord and subsequently in more cervical areas, with inclusion 
bodies that stain for SOD1, Hsp70, neurofilaments and ubiquitin. Vacuolization 
and gliosis are evident before clinical onset and before motor neuron death in 
the spinal cord and brainstem (Howland et al., 2002).
Furthermore, mice carrying naturally occurring autosomal recessive mutations 
on unidentified genes provide animal models with motor system impairment. 
PMN mice show a progressive motor neuronopathy characterised by paralysis of 
the limbs, neurogenic atrophy of muscles, axonal degeneration but with relative 
sparing of motor neuron cell body. The PMN locus was identified on 
chromosome 13, but the gene involved is not known (Brunialti et al., 1995).
The wobbler mice represent another model of motor neuron disease. They show 
a progressive forelimb weakness associated with proximal axonal degeneration 
and vacuolar changes within the anterior horn cells of the spinal cord with a 
little involvement of the brain. In this case, the gene responsible for this 
syndrome has been mapped on chromosome 11 (Kaupmann et al., 1992), and 
recently has been identified as a missense mutation in Vps54 gene associated 
with vacuolar vesicular sorting factors involved in the vesicular trafficking 
(Schmitt-John et al., 2005).
Mice showing neuromuscular degeneration, with autosomal recessive mutation 
localized on the gene coding for the ATPase/DNA helicase were described
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(Cook et al., 1995; Cox et al., 1998). Called nmd mice, they present rapidly 
progressive hindlimb weakness and motor neuron cell body degeneration. 
Another spontaneous animal model of motor dysfunction is represented by mnd 
mice, considered in the past a model of ALS. These mice develop a late onset 
motor neuron degeneration characterized by progressive deterioration of motor 
function which is more severe in the lumbosacral than in the other regions, as 
well as variable pathology in the lower cranial nerves (Messer et al., 1987). 
However, the number of choline acetyltransferase (ChAT) immunopositive 
lumbar motor neurons is not different from normal mice (Mennini et al., 2002). 
The MND mice carry a spontaneous homozygous mutation in the coding region 
of the gene Cln8 belonging to the family of neuronal ceroid lipofuscinose- 
related genes (CLNs) (Ranta et al., 1999). Thus, the presence of abnormal 
autofluorescent cytoplasmic inclusions rich in lipofuscin found in neurons, but 
also in many other somatic organs, makes these animals a useful model for 
human neuronal ceroid lipofuscinosis rather than for ALS (Bronson et al., 
1993).
Recently, Ahmad-Annuar and colleagues have described another mutant mouse 
model of motor neuron disease, the legs-at-odd-angles (Loa) mutant. In these 
mice mutations in the cytoplasmic dynein heavy chain gene (Dnchcl) cause 
motor neuron degeneration. Mice exhibiting the Loa phenotype suffer 
progressive loss of locomotor function and homozygous animals have neuronal 
inclusion bodies that are positive for SOD1, CDK5, neurofilament and ubiquitin 
proteins (Hafezparast et al., 2003). As this phenotype reproduces some aspects 
of human motor neuron degeneration disorders, it is possible that dynein may be 
a causative gene or susceptibility factor in human motor neuron disease.
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However, to date, no association between familial motor neuron disease and the 
genotypes presented by Loa mice has been found.
All these mice strains offer several advantages in the study of early phenomena 
occurring in a motor neuron disorder, involving a progressive and naturally 
occurring impairment of motor system. However, many features are quite 
dissimilar from human ALS pathology. Moreover, it is possible that the genetic 
alterations affecting these mice and the associated biochemical defects do not 
contribute to the human disease. Thus, these models are not particularly reliable 
for testing therapeutic intervention or uncovering disease mechanisms, 
althought the study of the pathology occurring in these mouse models may 
contribute to the discovery of still unknown risk factors for human ALS.
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1.8 THE THERAPY FOR AMYOTROPHIC
LATERAL SCLEROSIS
No cure for ALS patients so far is available, and the only drug approved in the 
1996 by the Food and Drug Adminstration is riluzole (Miller et al., 1996), 
although it produces only a modest effect in prolonging the survival of patients 
and mouse models by a few months (Gurney et al., 1998; Riviere et al., 1998). 
Different mechanisms were proposed by experiments in vivo and in vitro for 
this drug, such as inhibition of the release of glutamate due to the inactivation of 
voltage-dependent Na+ channels on nerve terminals, as well activation of a G- 
protein dependent signal transduction process (Doble, 1996). Furthermore, it 
was demonstrated that riluzole can block some of the postsynaptic effects of 
glutamate by non-competitive inhibition of NMDA and AMPA receptors 
(Doble, 1996; Albo et al., 2004). In addition, it has been demonstrated in ALS 
patients using proton magnetic resonance spectroscopy that riluzole reduces the 
amount of motor neuron loss during the progression of the disease (Kalra et al., 
1998).
Other pharmacological approaches were attempted to block or ameliorate the 
motor neuron loss, among them, the use of specific neurotrophic factors such as 
BDNF (Brain Derived Neurotrophic Factor) and IGF-1 (Insulin growth factor). 
Several studies have shown a neuroprotective effect in animal models for these 
trophic factors, evidenced by preserving the morphology of motoneurons, 
decreasing gliosis and increasing the lifespan of SOD1 transgenic mice. For 
IGF-1 two clinical trials were carried out in North America that have shown an 
opposing effect; however only one resulted in an improved life span (Lai et al.,
1997). Furthermore, a European trial have confirmed the lack of efficacy of this
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factor (Borasio et al., 1998). Also for BDNF, different trials were carried out in 
America and in North America utilizing subcutaneous and intrathecal 
administration. However no amelioration of the progression of the disease was 
detected (Clinical Trial Summary, Motor Neuron Disease Association Web 
site). Vascular endothelial growth factor (VEGF) also has a neuroprotective 
effect on motoneurons and increases the lifespan of SOD1 mutant mice and rats 
(Azzouz et al., 2004; Storkebaum et al., 2005). Furthermore, VEGF has been 
shown to be a modifier of motor neuron degeneration in ALS patients 
(Lambrechts et al., 2003).
Recently, it has been demonstrated that the method of delivery of a treatment is 
important. An interesting example is treatment with IGF-1 or VEGF 
retrogradely transported in motoneurons through viral vectors that were injected 
into muscles (Kaspar et al. 2003; McGeer and McGeer 2005). This produced 
one of the best results obtained in mice models, even when delivered at the time 
of clear disease symptoms.
Other drugs were proposed and tested such as the tetracycline antibiotic 
minocycline, whose role seems to be to inhibit p38 mitogen activated protein, 
cytochrome C released from the mitochondria, inducible nitric oxide synthetase 
(iNOS), caspase 3 and 1 (Tikka et al., 2001; Zhu et al., 2002). This drug has 
shown promising effect on culture cells and in animal models of different 
pathology such as Parkinson’s disease, stroke, trauma, and Huntinghton Disease 
(Yijanheikki et al., 1998; Yijanheikki et al., 1999; Chen et al., 2000; Wu et al., 
2002). In addition, a positive effect has been detected in transgenic mouse 
model of ALS (Kriz et al., 2002; Zhu et al., 2002). A trial has been opened for 
this drug that has reached the phase III.
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Interesting neuroprotective effects was shown in transgenic mouse model for 
creatine, which acts on reduced energy metabolism and/or mitochondrial 
dysfunction (Klivenyi et al., 1999) or cyclooxygenase 2 inhibitors (Klivenyi et 
al., 2004), and has an anti-inflammatory effect. However, no effect was 
demonstrated using these drugs in ALS patients (Shefiier et al., 2004).
Other substances able to reduce the glutamate excitotoxicity were considered 
such as ceftriaxone which, among other effects, increases the expression of 
GLT1 and moderately prolongs the survival of SOD1G93A mice (Rothstein et 
al., 2005). On this basis, a long-term double-blind clinical trial was proposed, 
despite the negative results obtained from eight clinical trials with short-term 
(five to eight weeks) ceftriaxone treatment (Beghi et al., 2005).
However, neither gabapentine nor topiramate, other antiglutamate drugs, exert 
beneficial effects in preclinical and clinical trials (Gordon, 2005). Instead, other 
anti-excitotoxic agents able to inhibit AMPA receptors have shown beneficial 
effects in mouse models (Canton et al., 2001; Van Damme et al., 2003; 
Tortarolo et al., 2006), and a clinical trial with talampanel has recently been 
proposed (Andersen et al., 2005).
A promising approach might be a simultaneous treatment using molecules that 
act on different targets. Indeed, animal studies have shown that combination 
therapies often have synergistic effects. For example, treatment with 
minocycline produces an additional beneficial effect in transgenic mice when 
administered with creatine (Zhang et al., 2003).
Promising effects have also been shown using cellular therapy by stem cells 
(Silani et al., 2002). A significant effect in prolonging the survival of 
SOD1G93A mice was reported in a study using human umbilical-cord blood 
cells injected intravenously (Garbuzova-Davis et al., 2003). Human neural
progenitor cells modified with GDNF (Klein et al., 2005), or Sertoli cells 
(Hemendinger et al., 2005), injected into the spinal cord of SOD1G93A rats 
induced a significant neuroprotection in the proximity of the site of 
implantation.
Furthermore, some studies have suggested that a high energy diet has a 
compensating effect on the energetic imbalance of the transgenic mouse model 
(Dupuis et al., 2004).
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1.9 GLUTAMATE RECEPTORS
The transmission of glutamate stimulus is regulated by four different receptors 
that can be subdivided in ionotropic and non ionotropic glutamate receptors. 
These can be furthermore subdivided such as listed:
• IONOTROPIC RECEPTORS
-AMPA
-Kainate
-NMDA
• NON IONOTROPIC RECEPTORS
-Metabotrophic receptors
The fundamental difference between these two kinds of receptors is that 
ionotropic receptors are ions channels, whereas non-ionotropic receptors act 
through an intracellular signaling cascade that can influence ions channels.
1.9.1 IONOTROPIC RECEPTORS
Ionotropic receptors are characterized by a multimeric structure composed of 
different subunits. They are divided based on pharmacological and structural 
similarities into NMDA (N-methyl-D-aspartate), AMPA (hlpha-amino-3-
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hydroxy-5-methyl-4-isoxazolepropionic acid) and Kainate receptors. They are 
structurally characterized by four transmembrane domains with an extracellular 
N-terminal and intracellular C-terminal. The second domain forms the channel 
pore through a re-entrant loop. A loop between the III and IV domains forms a 
binding site for the ligand (Standley and Baudry, 2000).
1.9.1.1 NMDA RECEPTORS
They are considered the most important glutamate receptor because they are 
able to regulate the calcium permeability in cells in physiological conditions. 
The ion influx is regulated by magnesium that is released in a voltage- 
dependent manner, and by a co-agonist glicine. Furthermore the activity is 
regulated by modulatory sites for polyamines, zinc ion, reducing agents and 
protons (Heath and Shaw, 2002). These receptors can be composed of different 
subunits: NR1, represented by 8 isoforms (Zukin and Bennett, 1995) and NR2, 
present in 4 isoforms, NR1 is always present in functional NMDA receptors 
whereas NR2 determines the pharmacological and physiological properties of 
the receptor (Meguro et al., 1992). An ubiquitous distribution of NR1 was 
demonstrated, whereas NR2 is much more localized in specific sites. A third 
subunit has been found recently, NR3, whose role so far has not been 
characterized (Das et al., 1998).
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19.1.2 AMPA RECEPTORS:
Originally identified based on its activation by non selective agonists, it was 
subsequently demonstrated to be activated selectively by a more specific 
agonist, a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA). 
Structurally it is composed of 4 different subunit proteins (GluRl-2-3-4) in a 
homomeric or heteromeric composition derived from different genes.
Current models for the topology of GluRs suggest that they comprise an 
extracellular amino terminal with consensus glycosylation sites, four 
hydrophobic membrane associated domains of which 1, 3 and 4 are 
transmembrane spanning while the second forms a reentrant loop, and an 
intracellular carboxyl terminal region with consensus phosphorylation sites 
(Fig. 1.1)
Fig 1.1: GIuR receptor structure
N'terminat
M1 M3
C-terminal
A functional AMPA receptor differs in subunit composition depending on both 
nervous system region and neuronal subtype. AMPA receptor composition is
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not rigid but it can change and is dynamically influenced by the environmental 
conditions (Luscher et ah, 2000; Zhou et al., 2001). The most important 
subunits able to regulate calcium entry are the GluR2 subunits, that have an 
editing site in the second transmembrane domain Q/R site which is able to 
change a glutamine with an arginine in an edited state (Michaelis, 1998; 
Dingledine et al., 1999) (Fig. 1.2).
This site is developmentally regulated and completely edited with the arginine 
in the postnatal mammal. The presence of GluR2 in the composition of the 
AMPA receptors determines through a positively charged argininine a block on 
calcium entry. Other splicing and editing that determine different amminoacidic 
sequences characterize the AMPA receptor subunits. A FLIP/FLOP isoform 
variant defined by a 30 amino acids cassette and an editing site R/G 
(arginine/glycine) located in the loop between the third and fourth 
trasmembrane domain determines the desensitized state of the receptor once 
activated. An increased capacity of desensitization of AMPA receptors with a
Fig 1.2: Q/R editing site
xxyx> Wo&xt&Xttxx Jrxxxxxx;
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FLOP isoform rather with a FLIP isoform has been demonstrated (Myers et al.,
1998). Furthermore, a glycine instead of the arginine in the R/G determines an 
increased return to the activated state of the AMPA receptors. Hence, an altered 
regulation at these sites is able to result in a dysfunction in the homeostasis of 
ion influx, with deleterious consequences for the neuronal cell involved.
A much fast kinetics characterizes these receptors in comparison to NMDA 
receptors when activated in synaptic transmission.
1.9.13 KAINATE RECEPTORS:
This kind of ionic receptor is distinguished from NMDA and AMPA receptors 
by a selective activation by the kainate agonist. Structurally they have a similar 
amino acid sequence to AMPA receptor subunits, with 4 transmembrane 
domains with a N-extracellular and a C-intracytoplasmic domain. However, 
they have a particular N-terminal sequence that leads to specific binding by the 
kainate agonist. A functional receptor is characterized by heteromeric assembly 
of 5 different subunits: GluR 5-6-7 and KA 1-2, with the particular subunit 
composition determining the receptor’s pharmacological and functional 
properties.
Also in this case, an editing or a splicing activity gives rise to kainate receptors 
having different ion conductance and desensitization.
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1.9.2 NON-IONOTROPIC RECEPTORS
A completely different structure and function is associated with this type of 
glutamate receptor in contrast to the ionotropic receptors. They belong to the G- 
protein coupled receptor family with eight transmembrane domains.
1.9.2.1 METABOTROPIC RECEPTORS:
Each receptor can be functionally constituted by eight different subunits 
(mGLURl-8) which are grouped in three major families: Group I represented 
by mGluRl and mGluR5 having a transduction mechanism associated with 
postsynaptic inositol phosphate metabolism. In contrast mGluR2, 3 and 
mGluR4, 6, 7, 8 have been associated respectively with the Group II and Group 
III. Both are coupled to an inhibitory cAMP cascade in many expression 
systems. These receptors were located frequently at the presynaptic membrane, 
with the role of modulating the function of glutamate at this site (Heath and 
Shaw, 2002).
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Fig 1.3: Ion Channels
Ion channels are pore-forming proteins that help to establish and control the 
small voltage gradient across the plasma membrane of all living cells by 
allowing the flow of ions down their electrochemical gradient.
L-Glutamate is the major excitatory neurotransmitter in the mammalian CNS, 
acting through both ligand gated ion channels (ionotropic receptors) such as 
NMDA, AMPA and Kainate receptors and G-protein coupled (metabotropic) 
receptors. Activation of these receptors is responsible for basal excitatory 
synaptic transmission and many forms of synaptic plasticity such as long-term 
potentiation (LTP) and long-term depression (LTD). Noteworthy for the 
excitotoxicity events are the ligand gated calcium channels such as NMDA and
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AMPA. Others receptors are able to regulate the calcium entry such as voltage 
gated calcium channels (VGCC).
1.10 REGULATORY MECHANISMS OF 
CALCIUM ENTRY BY AMPA RECEPTORS
The calcium entry through AMPA receptors is regulated by different molecular 
features of their own subunits, such as: the presence of edited form of the GluR2 
subunit, channel desensitization, and receptor density on the cell’s surface.
1.10.1 EDITED FORM OF THE GLUR2 SUBUNIT
A post-transcriptional change through the editing of adenine (A) to inosine (I) in 
the receptor RNA leads to an editing changes CAG into CIG (Sommer et al., 
1991; Kim et al., 1994; Melcher et al., 1996), hence a substitution of the 
Glutamine (G) with the Arginine (R) at the Q/R site located in the second trans­
membrane domain of the AMPA receptor subunit. All of the AMPA receptor 
subunit genes encode glutamine at this Q/R site; however GluR2 alone is 
featured for the presence of an R substitution at this level determining a block of 
the calcium entry. This editing has an efficiency of 100% in the mammalian 
neurons from an embryonic stage throughout life (Bumashev et al., 1992; Nutt 
and Kamboj, 1994). The enzyme involved in the editing of GluR2 is adenosine 
deaminase acting on RNA type 2 (ADAR2) (Melcher et al., 1996; Higuchi et 
al., 2000). Hence, the presence at least of one edited GluR2 subunits determines 
a block of calcium permeability, whereas the presence of the unedited subunits 
determine an increase influx of this ion leading to excitotoxic events (Hollmann 
et al., 1991; Hume et al., 1991; Verdoom et al., 1991; Bumashev et al., 1995; 
Kuner et al., 2001).
1.10.2 CHANNEL DESENSITIZATION
Another mechanism of modulation that enables the regulation the homeostasis 
of calcium is the kinetics of desensitization of the receptor, which determines 
the resting state of the AMPA receptors. An aminoacidic substitution (arginine 
R/glycine G) in the loop between the third and fourth transmembrane domain at 
the R/G site and a cassette of 38 aminoacids that exist in two different forms 
(FLIP-FLOP) regulates the potential desensitization of these receptors. It was 
demonstrated that the edited glicine substitution in the R/G site has a faster 
recovery from desensitization state that the unedited arginine isoform (Lomeli et 
al., 1994). Two enzyme called ADAR1 and ADAR2 catalyze the editing for 
GluR 2, 3 and 4 (Melcher et al., 1996; Higuchi et al., 2000). Furthermore, it has 
been demonstrated that the FLIP form desensitizes more slowly than the FLOP 
isoform (Sommer et al., 1990; Lambolez et al., 1996), leading to an increased 
calcium entry.
1.10.3 RECEPTOR TRAFFICKING AT THE POSTSYNAPTIC SPACE
AMPA receptors change dynamically and their trafficking is regulated by 
peculiar proteins. An altered trafficking of the AMPA receptor subunits to the 
postsynaptic membrane could lead to an uncontrolled influx of ions in the 
cytoplasm, breaking the mechanism that regulates this homeostasis.
Recently several proteins were discovered to regulate trafficking of glutamate 
receptors between the cytoplasm and the membrane. The proteins involved in 
the trafficking of the GluR subunits interact with a specific amino acidic
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sequence localized in the intracellular cytoplasmic tails of the glutamate 
receptors and they themselves contain in their sequence a PDZ domain (Post­
synaptic density-95/Discs large/Zona occludens-1) (Doyle et al., 1996). PDZ is 
a modular domain for protein-protein interaction also known as Discs-Large 
homology Repeats (DHR) of approximately 100 amino acid domains originally 
identified on repeated regions of the synaptic protein PSD-95 in the brain, in the 
Drosophila septate junction protein Discs-Large, and in the epithelial tight 
junction protein ZOl (Woods and Bryant, 1991; Cho et al., 1992; Willott et al.,
1993). PDZ sequence is considered a modular protein-protein interaction motif 
that serves to localize proteins to specific subcellular sites.
PDZ domain-containing proteins have been shown to mediate protein-protein 
interactions during receptor and ion channel clustering and to recruit kinases 
and phosphatases to their membrane-associated substrates. Certain PDZ 
domains have also been shown to homooligomerize, thereby contributing to the 
formation of multiprotein complexes at specific subcellular sites (Brenman et 
al., 1996).
A splice cassette dictating long and short forms of the subunit was detected in 
the C- terminal of both GluR2 and GluR4 subunits (Gallo et al., 1992; Kohler et 
al., 1994). The predominant form of GluR2 is the short version (GluR2short) 
with less than 10% of the GluR2 transcripts in mouse brain encoding 
GluR21ong (Kohler et al., 1994). GluR4short is expressed preferentially in 
granule neurons of the cerebellum and Bergmann glial cell bodies. The 
GluR41ong form is restricted to Bergmann glial cells in the cerebellum, but is 
also expressed neuronally in the forebrain, mostly in intemeurons (Gallo et al., 
1992). Long variants have C-terminal domains that contain 68-81 amino acids 
while short isoforms contain 50 residues. Both long and short variants of each
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subunit are identical up to a lysine residue located 14 amino acids downstream 
of the last membrane domain (M4). In the short forms of GluR2 and GluR4 the 
entire C-terminal is encoded on the same exon that encodes for M4 whereas in 
the long splice variants the remaining C-terminal is encoded by the next exon 
which contains the 3% untranslated region of short isoform. To date, no short 
form of GluRl or long version of GluR3 has yet been detected (Gallo et al., 
1992; Hollmann and Heinemann, 1994; Kohler et al., 1994). The short (but not 
the long) forms of the AMPA receptor subunits contain a T:S X V-like motif 
(also called PDZ-binding motif) at the extreme C-terminal. This motif interacts 
with proteins containing a PDZ domain and the interaction is thought to localise 
proteins to specific subcellular regions. It has been proposed that the PDZ 
domain provides an important mechanism for clustering ion channels and 
receptors to the plasma membrane and for directing kinases and phosphatases 
toward their substrates.
Differences were revealed in the C-terminal domains of the GluR subunits. 
GluRl, 4 and a splicing form of the GluR21ong have longer cytoplasmic tails 
that are highly homologous (Kohler et al., 1994; Kolleker et al., 2003). 
Whereas, GluR2short, 3 and a splicing isoform of the GluR4short have shorter 
cytoplasmic homologous tails (Gallo et al., 1992; Kawahara et al., 2004a). Each 
subunit interacts with specific trafficking proteins that regulate the clustering in 
the membrane and in the subcellular compartment. The proteins involved in this 
trafficking can be subdivided into the group-1 PDZ proteins such as synapse 
associated protein 97 (SAP-97) that interact with the GluRl subunits (Leonard 
et al., 1998), whereas GluR2-3-4 interact with the group-2 PDZ proteins 
represented by protein interacting with C-kinase 1 (PICK-1) (Dev et al., 1999), 
glutamate receptor interacting protein type 1 (GRIP1) and type 2 (GRIP2, also
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know as AMPA receptors binding proteins; ABP). Another important no PDZ 
protein involved in the clustering of the AMPA receptor subunits into the 
membrane is NSF (N-ethylmaleimide sensitive fusion protein). Different 
features can be associated to these proteins and will be mentioned later.
The surface expression of the AMPA receptors cycle in a constitutive mode in 
and out of the plasma membrane (Luscher et al., 1999; Malinow et al., 2000; 
Carroll et al., 2001). AMPA receptor internalization from the cell surface occurs 
via a clathrin-mediated dynamin-dependent pathway and is stimulated by a 
variety of factors that induce synaptic depression (Carroll et al., 1999; Beattie et 
al., 2000; Ehlers, 2000; Lin et al., 2000; Man et al., 2000; Wang and Linden,
2000). Furthermore, recent studies of AMPA endocytosis suggest different 
pathways of internalization of the AMPA receptors sorting to an endosomal 
compartment ready to be recycled to the surface or to a lysosomal compartment 
where they may be degraded (Ehlers, 2000; Lin et al., 2000). This supports the 
idea that there are two distinct pools of synaptic AMPA receptors, one that can 
be regulated by activity and one that serves a maintenance function (Carroll et 
al., 1999; Daw et al., 2000; Malinow et al., 2000; Carroll et al., 2001; Shi et al.,
2001)d
1.10.4 PHOSPHORYLATION STATE OF THE AMPA RECEPTORS
A control of the regulated equilibrium between the cytosol and the membrane is 
associated also with the direct phosphorylation at multiple sites in the C- 
terminal tails of the AMPA receptor subunits. The phosphorylation of the 
AMPA receptor subunits can also modify the electrophysiological and
biochemical (synthesis and subunit composition) properties of the AMPA 
receptor subunits.
Recent studies have shown that the AMPA receptor subunits can be 
phosphorylated on their subunits GluRl, GluR2, and GluR4. The amino acids 
phosphorylated are serine, threonine, or tyrosine on the intracellular C-terminal 
domain. Several protein kinases, such as protein kinase A (PKA), protein kinase 
C (PKC), Ca2+/calmodulin-dependent protein kinase II (CAMKII), and tyrosine 
kinases are involved in the site-specific regulation of the AMPA receptor 
phosphorylation.
Using site directed mutagenesis and phosphopeptide mapping analysis, two 
major phosphorylation sites on the serine 831 and serine 845 residues of the 
GluRl C-terminus have been identified (Fig 1.3). These sites are specifically 
phosphorylated respectively by PKC and PKA, and it has been demonstrated 
that the latter is able to augment the AMPA receptor current (Roche et al., 
1996). Others studies have demonstrated that serine 831 can also be
94-phosphorylated by Ca /calmodulin-dependent protein kinase II (CaMKII) 
(Mammen et al., 1997; Strack et al., 1997; Vinade and Dosemeci, 2000), 
potentiating the GluRl current (Lledo et al., 1995; Lisman and Zhabotinsky, 
2001; Poncer et al., 2002). Furthermore, there is evidence that the 
phosphorylated forms of GluRl facilitate the incorporation of AMPA receptors 
into synapses (Esteban et al., 2003).
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Fig 1.4: Amino acid sequence in the GluRl C terminus
Phosphorylation sites on the Ser831 and 845 residues o f the GluRl subunit
Another subunit that also contains potential sites for protein phosphorylation is 
GluR2. Experiments of single site mutagenesis have demonstrated that the 
phosphorylation occurs on serines 863 and 880 of the C-terminus (Fig 1.4) 
(Matsuda et al., 1999; McDonald et al., 2001). The latter has been demonstrated 
to be phosphorylated by PKC (McDonald et al., 2001). In addition, GluR2 C 
terminus has multiple tyrosine residues underlying phosphorylation as tyrosine 
876, a last tyrosine residue within the C terminal PDZ ligand domain which is 
phosphorylated by nonreceptor Src family tyrosine kinases. Interesting, the 
binding domain of some trafficking proteins such as ABP, GRIP and PICK1, 
overlaps with the phosphorylation sites on tyrosine 876 and serine 880. The 
phosphorylation status on these sites affects the association of the AMPA 
receptor subunits with the interacting proteins, thereby modifying trafficking 
and distribution of the receptor. Indeed, a disrupted interaction of GluR2 with 
GRIP leading to reduced surface expression has been revealed after 
phosphorylation of Glur2 (Chung et al., 2000; Hirai, 2001).
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Fig 1.5: Aminoacid sequence in the GluR2 C terminus
Phosphorylation sites on the Ser863, Ser880 and Tyr876 residues o f the GluRl
subunit
In GluR4 the phosphorylation site was identified on serine 842 within the C 
terminal domain (Carvalho et al., 1999). Several kinases are able to 
phosphorylate in vitro serine 842, including PKA, PKC and CAMKII. 
Furthermore, another consensus site on threonine 830 was identified as a 
phosphorylation site for PKC (Pearson and Kemp, 1991) (Fig 1.5). PKA 
phosphorylation of GluR4 lead AMPA receptor subunits into synapses (Esteban 
et al., 2003)
Gll*R4; EFCYKSRAEAKRM KLTFSEAIRNKARLSITGSVGENGRVLYPOCPKAVHTGTAIRQSSGLAVIASDLP
m m o  Ser842
Fig 1.6: Aminoacid sequence in the GluR4 C terminus
Phosphorylation sites on the Thr830 and Ser842 residues o f the GluR4 subunit
The GluR3 subunit has a limited number of serine residues on its intracellular C 
terminal domain (Fig 1.6). So far, phosphorylation of this subunit has not been 
reported.
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GltiRl: EFCYKSRAESKRMKLTKNTQNFKPAPATNTQNYATYREGYNVYGTESVKI
Fig 1.7: Aminoacid sequence in the GluR3 C terminus
No phosphorylation sites in the C terminus aminoacidic sequence o f the GluR3
subunit
Other mechanisms of phosphorylation of AMPA receptor subunits were 
suggested. A recent study has demonstrated that the activation of NMDA 
receptors dephosphorylates serine 845 of the GluRl subunit in hippocampal 
slices (Vanhoose and Winder, 2003). This dephosphorylation resulted through 
the displacement of PKA from synapses by NMDA (Snyder et al., 2005). In 
addition, activation of phosphatase may contribute to this process because 
NMDA induced dephosphorylation of serine 845 was blocked by a phosphatase 
inhibitor (Vanhoose and Winder, 2003)
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1.11 AMPA RECEPTOR TRAFFICKING 
PROTEINS
1.11.1 GRIP-1
Using the yeast two-hybrid system, it has been demonstrated that the carboxyl 
termini of the GluR2 and GluR3 subunits interact with a 130 kDa protein 
termed GRIP-1 (Glutamate Receptor Interacting Protein-1) (Dong et al., 1997). 
GRIP-1 contains seven PDZ domains, but only the fourth and fifth PDZ 
domains bind to the GluR2 and GluR3 subunits (Fig 1.7). The other PDZ 
domains do not interact with AMPA receptors and may serve to anchor these 
receptors to the cytoskeleton or to other regulatory proteins.
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Fig 1.8: GRIP-1 structure and PDZ site interaction in GluR
Interaction o f the 4th and 5th PDZ domains o f the GRIP-1 with a ESVKI motif in 
the PDZ region o f GluR2 and GluR3 subunits
GRIP-1 interacts with an ESVKI motif in the PDZ region of GluR2 and GluR3 
that includes a crucial internal serine and a hydrophobic side chain on the 
terminating amino acid. GRIP-1 appears to be concentrated at some, but not all, 
excitatory synapses in cultured neurons.
Studies of subcellular localization by postembedding immunogold electron 
microscopy have shown in adult rat cortex a considerable synaptic staining and 
an intracellular labelling within the spines and dendritic shafts. However, a large 
proportion of GRIP-1 is not associated with excitatory synapse (where AMPA 
receptors are presumed to be concentrated) but with GABAergic neurons 
(Wyszynski et al., 1999).
Furthermore, recently it was demonstrated that GRIP-1 is required for the 
synaptic accumulation of the AMPA receptors. GRIP-1 might accomplish this 
either by promoting receptor insertion into the synaptic membrane (Osten et al., 
2000; Song and Huganir, 2002; Liu and Cull-Candy, 2005) or by anchoring it to 
the cytoskeleton through the PDZ domains (Braithwaite et al., 2002; Song and 
Huganir, 2002). In addition, a recent study has reported that GRIP-1 binds to 
kinesin 5 (KIF5, a microtubule-based motor protein that is important for 
vesicular transport to axons and dendrites) causing a complex that appears to be 
involved in the transport of GluR2 dendrites (Setou et al., 2002).
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1.11.2 ABP
ABP, is a post-synaptic density protein of 80 KDa related to GRIP-1 with two 
sets of three PDZ domains. It differs from GRIP-1 notably in lacking the C- 
terminal seventh PDZ domain. The C-terminal sequence ESVKI shared by 
AMPA receptor GluR2/3 subunits is reported to bind selectively to the third, 
fifth and sixth PDZ domains of ABP (Srivastava et al., 1998) (Fig 1.8).
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Fig 1.9: ABP structure and PDZ site interaction in GluR
Interaction of the 3rd, 5th and 6th PDZ domains of the ABP with a ESVKI motif in 
the PDZ region of GluR2 and GluR3 subunits
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It exhibits a widespread CNS expression and has been demonstrated to interact 
in a similar way to GRIP-1 with the GluR2 and 3 AMPA receptor subunits 
(Srivastava et al., 1998; Srivastava and Ziff, 1999). Furthermore, examining the 
subcellular distribution of ABP by electron microscopy has confirmed a high 
localization in the PSD fraction (Srivastava et al., 1998). ABPs can multimerize 
among themselves or with GRIP. A variant of the ABP, termed ABP-L/GRIP2 
protein, has been characterized as a splice variant of ABP containing an N- 
terminal extension of 52 aa, an internal deletion of 41 aa between PDZ3 and 
PDZ4, and a C-terminal extension that contains an additional seventh PDZ 
domain. GRIP-2 has the greatest similarity also with GRIP-1, sharing a highest 
homology for the sixth PDZ domain (Wyszynski et al., 1999). There is not a 
definitive explanation about the role of ABP and GRIP in the AMPA receptor 
trafficking. It has been demonstrated by a mutant GluR2 constructs that could 
not bind GRIP/ABP that the internalized receptors are stabilized in an 
intracellular pool by these proteins, preventing them from recycling back to the 
plasma membrane or to a degradative pathway (Braithwaite et al., 2002). This 
was confirmed also by electrophysiological results using a peptide that 
interferes with the GluR2-GRIP/ABP interaction, which was able to cause a 
run-up of excitatory postsynaptic currents due to the cycle back to the synaptic 
membrane of the subunits (Daw et al., 2000). In contrast, mutating the 
GRIP/ABP binding domain caused a decrease in the surface expression of a 
myc-tagged GluR2 construct expressed in hippocampal cultures by using 
Sindbis virus mediated gene delivery (Osten et al., 2000). Another study in 
hippocampal slices cultures using Sindbis virus to express mutant forms of 
GluR2 observed that synaptic delivery of GluR2 appeared to be completely
prevented by mutations that interfered with binding to NSF or GRIP/ABP (Shi 
et al., 2001)
1.11.3 PICK-1
PICK1 was originally isolated due to its interaction with protein kinase C 
(PKCa) (Staudinger et al., 1995; Staudinger et al., 1997) by the yeast two 
hybrid system as a protein of 416 aa with a molecular weight of 46.5 KDa. In 
the PICK1 protein sequence was identified a PDZ domain that interacts with a 
corresponding PDZ-binding domain QSAV at the extreme COOH terminus of 
PKCa (Staudinger et al., 1997) (Fig 1.9).
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Fig 1.10: PICK1 structure and PKC interaction
Interaction of the PDZ domain of the PICK1 with a QSAV motif in the 
aminoacidic sequence of PKC
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PICK1, unlike GRIP and ABP, has only one PDZ domain that can interact with 
the AMPA receptor subunits or PKCa, but contains a coiled domain that could 
potentially be involved in the dimerization of PICK1 interacting with several 
proteins containing PDZ domains. PICK-1 mRNA was demonstrated to have an 
ubiquitous distribution, with the highest expression in the brain and testis 
(Staudinger et al., 1995). A study of distribution at subcellular level in 
transiently transfected COS cells showed that PICK1 is located in the 
perinuclear region, the rough endoplasmic reticulum and Golgi apparatus 
(Staudinger et al., 1995), but it was colocalized also with excitatory synapses 
(Xia et al., 1999). PICK1 is an efficient substrate for PKC phosphorylation both 
in vivo and in vitro, but the PKCa binding and phosphorylation of PICK1 
appear not to be correlated with the activity since PKCa binds phosphorylated 
and unphosphorylated PICK1 with the same abilities. It was also speculated that 
the function of PICK1 is to localize activated PKCa to the plasma membrane, 
thereby bringing the kinase in proximity with specific substrates (Staudinger et 
al., 1997). Noteworthy, AMPA receptors are known to be regulated by 
phosphorylation and PKC is a strong candidate kinase for mediating at least part 
of the changes in receptor phosphorylation (McGlade-McCulloh et al., 1993; 
Roche et al., 1994).
A recent study has demonstrated an interaction between the AMPA receptor 
subunits and PICK1 through PDZ domains. The interaction occurs within the 
last ten amino acid residues containing a PDZ binding motif (E S V:I K I) of the 
short C-terminal alternative splice variants of AMPA receptor subunits. 
However, no interaction was revealed by the authors with the corresponding 
long splice variants which do not contain the E S V:I K I motif (Dev et al., 
1999) (Fig. 1.10).
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Fig 1.11: PICK1 structure and PDZ site interaction in GluR
Interaction of the PDZ domain o f the PICK1 with a ESVIKI motif in the PDZ 
region of GluR2 and GluR3 subunits
A role for PICK1 as anchoring protein for GluR short subunits to intracellular 
membrane associated PKCa was proposed, conferring substrate specificity for 
the phosphorylation event of the AMPA receptors (Dev et al., 1999).
Two mechanisms were hypothesized in the trafficking of the AMPA subunits 
for PICK1 in Purkinje cultured cells. Assuming that ABP/GRIP is bound in the 
basal state, the GluR2/3 activation by the PKC responsible for Long Term 
Potentation (LTP) induction results in the phosphorylation of GluR2 Ser880. 
This causes the unbinding of GRIP/ABP and the recruitment of PICK1 to the
71
Synaptic GluR2/3 containing AMPA, which is then primed for internalization 
by clathrin-mediated endocytosis (Fig. 1.11).
PKC
Fig 1.12: 1° mechanism proposed for AMPA trafficking and PICK1
Unbinding of GRIP1/ABP by phosphorylation in C terminal of the GluR 
subunits, which is mediated by PKC, recruits PICK1 to the GluR subunits 
priming the clathrin-mediated endocytosis
In another proposed mechanism, GRIP/ABP unbinding is sufficient to prime 
synaptic AMPA receptors for internalization. PICK1 binds AMPA receptors in 
the internal pool, stabilizing them and attenuating compensatory AMPA 
receptor insertion in the membrane (Xia et al., 2000) (Fig. 1.12).
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PKC
Fig 1.13:2° mechanism proposed for AMPA trafficking and PICK1
Unbinding of GRIP1/ABP by phosphorylation in C terminal o f the GluR 
subunits, which is mediated by PKC subunits, primes the clathrin-mediated 
endocytosis. Whereas PICK1 stabilizes the internal pool of them
Furthermore, in NIH3T3 cell culture it was demonstrated that the expression of 
PICK-1 has a role in the phosphorylation of the AMPA receptors by the protein 
kinase C (PKC), reducing the surface expression of them (Perez et al., 2001). 
Another study confirmed a role of PICK-1 in AMPA receptors endocytosis, 
demonstrating that cells loaded with a peptide that disrupts the GluR2-PICK-l 
interaction cause an increase in synaptic response and inhibited LTD (Kim et 
al., 2001). However, a different role in an opposite movement of the AMPA 
receptor subunits from intracellular stores to the synaptic membrane was
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suggested for PICK-1 and PKC in an electrophysiological study in the 
hippocampus (Daw et al., 2000).
1.11.4 NSF
NSF was first described in 1998 as a protein involved in membrane fusion 
events (Block et al., 1988). The step required for bilayer fusion of the vesicle 
with the target is facilitated by integral membrane proteins called soluble NSF 
attachment protein receptors (SNAREs). The cytoplasmic domains of these 
SNAREs form a stable coiled-coil complex that bridges the fusing membranes 
(trans configuration) and promotes fusion. Once fusion is complete, the SNARE 
complexes, originally spanning the two membranes, now reside in the same 
membrane (cis configuration). The cellular role of NSF is to disassemble these 
cis complexes so SNARE monomers can be recycled and vesicular transport is 
able to continue. NSF completes this function through an adaptor protein called 
SNAP (soluble NSF attachment protein), which binds to the SNARE complex 
and subsequently binds to and stimulates the ATPase activity of NSF (Rothman,
1994).
NSF acts as hexamer (Fleming et al., 1998) and through an ATP hydrolysis 
provides a driving force that dissociates this complex.
Each promoter is divided into three discrete domains and each domain is 
connected by a protease sensitive linker region. There is an amino-terminal 
NSF-N domain (1-205) followed by two ATP-binding domains NSF-D1 (206- 
477) and NSF-D2 (478-744) (Fig.1.13).
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Fig 1.14: NSF structure and no PDZ site interaction in GluR
NSF interacts specifically with no PDZ domain (starting from 834 to 854 
residue) in the C-terminus of the GluR2 subunits
It was determined at the ultrastructural level that NSF immunoreactivity is 
present in large dendritic shafts and in dendritic spines, as well as in axon 
terminals in the close vicinity of the postsynaptic membrane (Osten et al.,
Different evidences have suggested an important role of NSF also as a stabilizer 
of AMPA receptors in the plasma membrane, making them resistant to 
regulated endocytosis (Nishimune et al., 1998; Osten et al., 1998; Noel et al.,
1999).
It was demonstrated that NSF interacts exclusively with no PDZ C-terminal site 
of GluR2 subunit. This region was found to lie within a 21 aa sequence, starting
1998).
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from 834 to 854 residue (Osten et al., 1998). The presence of this NSF 
interaction domain seems to be specific for the C terminus of GluR2, as 
compared with other AMPA receptor subunits (Nishimune et al., 1998; Beretta 
et al., 2005).
Several models were proposed as functional models of NSF on the GluR2 
subunits:
It was demonstrated that NSF and a- and p-SNAPs interact with GluR2 in a 
complex that in several aspects resembles the interaction of NSF and SNAP at 
the SNARE complex. The interaction of NSF and SNAP with the AMPA 
receptor could involve the disruption of multiprotein complexes, such as those 
formed between the membrane-inserted receptor and the proteins of the 
postsynaptic density (such as GRIP or ABP) (Hanley et al., 2002). Furthermore, 
it has been demonstrated that NSF regulates selectively the interaction of GluR2 
and PICK1, disassembling PICKl-GluR2 complexes, resulting in an increased 
incidence of AMPA receptors at the cell surface (Hanley et al., 2002).
The role of the NSF in the AMPA receptors trafficking was studied by using 
peptides able to interfere with the interaction between GluR2 and NSF. These 
experiments have demonstrated a fairly rapid decrease in synaptic strength in 
cell culture (Nishimune et al., 1998; Song et al., 1998; Luscher et al., 1999; 
Noel et al., 1999), whereas with chronic exposure an almost complete block of 
trafficking of the AMPA receptors to the surface has been confirmed by 
electrophysiological observation (Luscher et al., 1999; Noel et al., 1999).
These results suggest that NSF is primarily important when synapses are 
stimulated, because only the regulated, but not the constitutive cycling of GluR2 
was affected by mutating its NSF binding domain.
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Other proteins were characterized to regulate the trafficking of the AMPA 
receptor subunits to the membrane such as Stargazing, a PDZ protein able to 
transfer and maintain the GluRs subunits into the membrane (Yamazaki et al., 
2004; Vandenberghe et al., 2005); whereas 4.1 family proteins are able to 
interact with GluRl and 4, controlling the transport and the stabilization to the 
membrane (Shen et al., 2000; Coleman et al., 2003).
NARP (neuronal activity regulated pentraxin), a presynaptic protein, instead 
plays an important role in the receptors aggregation to the cells surface. It has 
been also showed that the editing state FLIP/FLOP and at the Q/R site of the 
GluRs subunits influences the trafficking to the membrane surface. The 
expression of receptors containing both the FLIP and FLOP isoform is able to 
reach more easily the membrane than the homomeric receptors (Brorson et al., 
2004). Furthermore, the unedited form at the Q/R site is much more efficiently 
transferred to the membrane that the edited form (Greger et al., 2002; Greger et 
al.,2003)
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1.12 PATHOGENIC HYPOTHESES OF ALS
Different hypotheses were proposed to explain the cause of ALS pathology. The 
critical point, as in other neurodegenerative diseases, is the explanation of the 
selective vulnerability of a given cell population, namely the motor neurons in 
ALS.
1.12.1 OXIDATIVE DAMAGE
The role of oxidative stress as a primary or secondary event in the pathogenesis 
of ALS still remains controversial. Increase of oxidative damage markers such 
as protein carbonyl adducts, lipid peroxidation and DNA damage, were reported 
in human patients affected by both sporadic and inherited forms of ALS (Beal et 
al., 1997; Ferrante et al., 1997b; Liu et al., 1999) and in a transgenic mouse 
model of the disease (Ferrante et al., 1997a; Andrus et al., 1998; Liu et al., 
1998). However, in other studies, no significant differences in markers of 
oxidative damage associated with the expression of SOD1 mutants were found 
(Bruijn et al., 1997a). Evidence of increased oxidative insult was provided more 
consistently in sporadic ALS patients (Shaw et al., 1995a; Ferrante et al., 1997b; 
Pedersen et al., 1998).
Concerning the familial forms of ALS and SOD1 mutant transgenic mice, it was 
hypothesized that a possible source of oxidative insult may be represented by 
the gain of toxic function of mutated SOD1 (Cleveland and Rothstein, 2001). 
Yim and co-workers showed that mutations of SOD1 protein can decrease its
Km for hydrogen peroxide (Yim et al., 1996; Yim et al., 1997). The use of 
hydrogen peroxide as a substrate by the reduced SODl-Cu+ form might produce 
the extraordinarily reactive hydroxyl radical (OH') leading to a cascade of 
peroxidation (Wiedau-Pazos et al., 1996). Singh and colleagues demonstrated 
that a significant fraction of 5,5'-dimethyl-l-pyrrolline N-oxide (DMPO)/OH 
formed during the reaction of SOD1 and familial ALS SOD1 mutants with 
hydrogen peroxide (H2O2) is derived from the incorporation of oxygen from 
water due to oxidation of DMPO to DMPO/OH, presumably via DMPO radical 
cation. However, no differences were detected between wild type and mutant 
form of SOD1 (Singh et al., 1998).
Beckman and collaborators proposed that an altered folding of the enzyme 
caused by the mutations, might determine a grater access of abnormal substrates 
such as peroxinitrite (ONOO") to the catalytic copper site. This could lead to 
aberrant tyrosine nitration and numerous toxic events (Beckman et al., 1993). 
Another hypothesis suggests that mutations may reduce the amount of bound 
zinc, allowing a rapid reduction of mutant SOD1 to the Cu1+ form by abundant 
intracellular reductants. The reduced SOD1 mutant would then run the normal 
catalytic step backwards, converting oxygen to superoxide. The superoxide so 
produced would react with nitric oxide producing peroxynitrite, which would 
promote intracellular damage, including protein nitration (Estevez et al., 1999). 
The time course of accumulation of oxidative damage relative to disease onset 
and progression in ALS patients is not known. Even if oxidative damage is 
secondary and does not initiate toxic events, it is probable that oxidative stress 
contributes significantly to the neuronal death in ALS. Treatment with the 
antioxidant vitamin E (alpha-tocopherol) slowed down the onset and 
progression of paralysis in transgenic mice expressing SOD1 carrying the G93A
mutation (Gurney et al., 1996). However, a clinical trial carried out on ALS 
patients with the same drug did not ameliorate survival or motor function 
(Desnuelle et al., 2001).
1.12.2 MITOCHONDRIAL ALTERATIONS
Several lines of evidence suggest that mitochondrial dysfunction may be 
involved in the pathogenesis of ALS. Studies in human postmortem and biopsy 
samples have described mitochondrial abnormalities in proximal axons (Hirano 
et al., 1984b) and in the anterior horns of sporadic ALS spinal cords (Sasaki and 
Iwata, 1996). Subsarcolemmal aggregates of abnormal mitochondria were found 
in intramuscular nerves and skeletal muscle (Afifi et al., 1966; Atsumi and 
Miyatake, 1987), which also showed increased mitochondrial volume and 
calcium levels (Siklos et al., 1996). Furthermore, defects in the activities of 
mitochondrial respiratory chain complexes were detected in muscle and spinal 
cord of sporadic ALS patients (Wiedemann et al., 1998; Borthwick et al., 1999; 
Vielhaber et al., 2000; Wiedemann et al., 2002) suggesting that respiratory 
chain impairment may participate in the pathogenesis of SALS. Moreover, a 
decrease of COX activity was recently reported in motor neurons and muscle 
biopsies of sporadic ALS patients, suggesting a role in the mechanism of the 
disease (Borthwick et al., 1999).
Massive vacuolization of cytoplasm and swollen mitochondria were observed in 
the motor neurons of transgenic mice lines carrying the G93A or G37R 
mutation at the early stage of the disease (Dal Canto and Gurney, 1995; Wong
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et al., 1995; Bendotti et al., 2001a), suggesting that mitochondrial pathology is 
an early preclinical feature of motor neurons damage in these mice.
There is others evidences indicating that in the same mice a reduced amount of 
respiratory enzimes (complexes I and IV) in spinal cord and brainstem was 
present (Browne et al., 1998). More recently different studies have reported an 
accumulation of mutant SOD1 in the mitochondria of the spinal cord from 
SOD1G93A mice (Higgins et al., 2002; Liu et al., 2004). These findings support 
the hypothesis that mutant SOD1 may damage mitochondrial function and 
integrity directly from inside the mitochondria. Furthermore, mitochondrial 
alterations seem to be the early event in the vacuolization of the motor neuron in 
transgenic mice. The vacuoles are belived to be formed by the expansion of 
mitochondrial outer membrane which can be fused with membranes of other 
subcellular organelles (Bendotti et al., 2001a; Higgins et al., 2003). Moreover, 
SOD1 mutations not only cause mitochondrial morphological alterations, but 
also result in mitochondrial dysfunction, both in animal and cellular models of 
FALS. A significant loss of mitochondrial membrane potential, which is an 
indicator of mitochondrial respiratory chain dysfunction have been documented 
in neuroblastoma cells expressing mutant SOD1 (Cam et al., 1997). In addition, 
a decrease of ATP levels, impaired respiratory chain enzymes, and increased 
production of reactive oxygen species were demonstrated in motor neuron-like 
cells and neuronal cell lines expressing mutant SOD1 (Menzies et al., 2002; 
Beretta et al., 2003).
In SOD1G93A mice at an early disease stage, the activities of various 
mitochondrial electron transfer chain complexes were decreased in the spinal 
cord. This decrease persisted throughout the course of disease progression (Jung 
et al., 2002).
Additionally, indirect evidences that mitochondrial energy metabolism is 
impaired by mutant SOD1 was supported by the fact that administration of 
creatine, a molecule involved in energy storage, increases the lifespan of G93A 
mice (Klivenyi et al., 1999). A decrease in several respiratory chain complexes 
and in the capacity to consume oxygen and synthesize ATP have been also 
revealed in isolated mitochondria from brain and spinal cord of G93A mice 
(Mattiazzi et al., 2002).
Another group using isolated mitochondria from presymptomatic and 
symptomatic G93A mice has demonstrated that G93A mitochondria suffer from 
a loss of cytochrome c associated with the inner mitochondrial membrane 
leading to altered mitochondrial respiration (Kirkinezos et al., 2005). 
Furthermore, it was demonstrated that the elevation of the cytosolic calcium 
levels in neurons induces enhanced production of free radicals from 
mitochondria, and compromises mitochondrial integrity (Reynolds, 1999), 
although the mechanism underlying this damage is still unclear. Consistent with 
this evidence, Carri' et al. showed that neuroblastoma cells transfected with 
mutant SOD1 displayed increased cytoplasmic calcium levels, indicating a 
reduced calcium-buffering capacity (Carri et al., 2003).
A trigger stimulus to cell death by necrosis or apoptosis is the permeabilization 
of the mitochondrial membranes that can be induced through activation of the 
mitochondrial permeability transition pore (MPTP) (Kroemer and Reed, 2000).
The MPTP is a voltage-gated cation-permeable channel, whose opening is
• 2+favored by several factors including depolarization, intramatnx Ca 
accumulation and oxidizing agents like reactive oxygen species. All these can 
be altered in the motor neurons by the presence of mutated SOD1.
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Interestingly, it was demonstrated that the altered mitochondria appeared first in 
dendrites of the anterior horn of the spinal cord, than in cell bodies. Thus, it is 
possible that a synergistic effect between glutamatergic stimuli and the toxic 
effect of the SOD1 mutant in motor neurons may induce activation of the 
MPTP. This in turn would be able to permeabilize the mitochondrial 
membranes, with consequent mitochondrial osmotic changes and membrane 
swelling, and this may be the initial step of the cascade of events leading to 
motor neuron death. Consistent with this hypothesis is the finding that 
overexpression of Bcl2, an antiapoptotic factor, which is able to inhibit the 
opening of MPTP, delays the disease onset and prolongs survival in transgenic 
mice carrying mutated SOD1 (Kostic et al., 1997). Furthermore, treatment with 
coenzyme Q and creatine, both inhibitors of the MPTP, significantly prolonged 
the life span of transgenic mice carrying the G93ASOD1 mutant (Matthews et 
al., 1998; Klivenyi et al., 1999).
1.12.1.3 CYTOSKELETAL ABNORMALITIES
An important hallmark in the ALS pathology is the intermediate filament 
accumulation (IF). There are three major IF types expressed in adult neurons: 
neurofilaments, a-intemexin and peripherin. Neurofilaments (NF) are the most 
abundant neuronal IF proteins, being expressed in most neurons of the central 
(CNS) and peripheral (PNS) nervous systems (Julien and Mushynski, 1998; 
Gotow, 2000). They comprise three protein subunits, NF-L of 68-70 kD, NF-M 
of 150-160 kD and NF-H of 200-210 kD. Alpha-intemexin, a 66-kD protein, is 
expressed mainly in the CNS (Pachter and Liem, 1985). Peripherin, a 58-kD
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protein, is expressed mostly in the PNS and in some neuronal populations of the 
CNS (Portier et al., 1983; Parysek and Goldman, 1988).
These alterations were revealed in both sporadic and familial ALS (Hirano et 
al., 1984a; Hirano et al., 1984b) and in transgenic SOD1 mice (Julien et al., 
1998; Robertson et al., 2002). Small in frame deletions or insertions in the tail 
domain of the NFH neurofilament subunit were reported to occur in 1% of 
sporadic ALS (Al-Chalabi et al., 1999). However, these alterations do not seem 
to provoke by themselves motor neuron disease. In order to evaluate if 
neurofilament alterations is a key factor in the ALS pathology, transgenic mice 
with mutant neurofilament subunits have been developed. Several models have 
been generated as an increase gene expression of NF-L (Neurofilament Light) 
or NF-H (Neurofilament High). Cross breading with SOD1 transgenic mice 
slow down the progression of the disease through an accumulation of 
neurofilament in the cytoplasm rather than in the proximal axon, the latter being 
considered an important event in the block of the axonal trasport. This is likely 
due the neurofilament acting as a sink against harmful stimulus in the cell body 
(Couillard-Despres et al., 1998). However, other types of intermediate filament 
aggregates seem neurotoxic, such as those found in transgenic mice 
overexpressing either peripherin or an assembly-disrupting NF-L mutant 
(Beaulieu and Julien, 2003). However they do not appear to be particularly 
important in ALS motor neuron degeneration (Lariviere et al., 2003).
1.12.4 PROTEIN AGGREGATION
One consistent neuropathological feature of both the sporadic and familial 
forms of ALS is the presence of protein aggregation (Leigh et al., 1991; Bruijn 
et al., 1998; Bendotti et al., 2004). Aggregates have also been revealed in the
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motor neurons and in the astrocytes of SOD1G85R mice before the onset of 
clinical symptoms (Bruijn et al., 1997b), in SOD1G93A mice as a first 
neuropathological sign (Johnston et al., 2000; Cheroni et al., 2005) and in cell 
culture model system (Bruijn et al., 2004). One of the most represented proteins 
in the aggregate is SOD1 in an insoluble high molecular weight form (Johnston 
et al., 2000; Cheroni et al., 2005). The SOD1 aggregates have been classified in 
two classes. The first is represented by aggregates detectable by conventional 
histological stains and are characterized by intense and localized SOD1 
immunoreactivity throughout the inclusions or, less frequently, only at the 
periphery of them. The second type includes cell body deposits that are more 
diffusely distributed. Misfolded SOD1 aggregates can not be dissociated, even 
with strong detergents and reducing agents. Their harmful effects could result 
from altered catalytic activity mediated by the misfolded aggregated mutants, 
the cosequestering of essential cellular proteins such as chaperones and/or 
overload of the ubiquitin proteasome pathway, which degrades damaged 
proteins (Cleveland and Rothstein, 2001). Another aggregated protein revealed 
in human and ALS transgenic mice is the ubiquitin (Stieber et al., 2000; 
Watanabe et al., 2001; Bendotti et al., 2004). This evidence has lead some 
workers to think that the proteasome machinery is implicated in this pathology, 
given the role of ubiquitin in the degradation process through the proteosome 
(Kabashi et al., 2004; Cheroni et al., 2005). Another protein revealed 
accumulated in human and transgenic mice tissue is p38MAPK (Tortarolo et al., 
2003; Bendotti et al., 2004). This protein is linked to intracellular mechanisms 
of death and it was demonstrated to be able to phosphorylate neurofilament and 
activate transcription factors which in turn lead to cytokine expression. 
Furthermore, phosphorylated neurofilaments and dorfin, a RING-IBR type
ubiquitin ligase (E3) which can ubiquitinate mutant S0D1, were characterized 
in abnormal intracellular perikaryal aggregates (Bendotti et al., 2004; Ishigaki et 
al., 2004).
However, it is not yet clear what the role is of these aggregates in the disease 
pathogenesis, or whether they are harmless by-products, or potentially 
beneficial through the sequestration of abnormal proteins.
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1.12.5 INFLAMMATION
A clear evidence of an involvement of inflammation events characterizes the 
pathology of ALS. Activation and proliferation of microglia was found in 
regions of motor neuron loss, such as the primary motor cortex, brainstem 
motor nuclei, corticospinal tracts and the ventral horns of the spinal cord (Ince 
et al., 1996). Furthermore, post-mortem studies of familial and sporadic ALS 
revealed that activated microglia occurred not only in areas of severe motor 
neuron loss, but also in regions where there was only mild motor neuron 
damage (Ince et al., 1996). This suggests that microglia are activated early in 
the pathogenesis of human ALS. This was supported by the evidence of an 
increased binding of peripheral benzodiazepine, a marker for activated 
microglia, in the brain of ALS patients at the onset of the disease as detected by 
positron emission tomography (PET scan) (Turner et al., 2004). It was also 
documented that an activation of microglia and astrocytes characterize the 
progression of the disease of the transgenic mice already at the presymptomatic 
stage of the disease (Kawamata et al., 1992; Hall et al., 1998; Sargsyan et al., 
2005). However, an elegant work recently published has confirmed an 
involvement of the microglia exclusively during the progression of the disease, 
showing that diminishing selectively the mutant human SOD1 in the microglia 
of the transgenic mice had little effect on the early disease phase but sharply 
slowed later disease progression (Boillee et al., 2006).
Furthermore, several studies have also demonstrated an increase expression of 
proinflammatory mediators (TNF-a, IL6) in the serum of ALS patients 
(Sekizawa et al., 1998; Poloni et al., 2000) and increased levels of TNF-a, IL- 
lb, IL-6 TGFbeta, iNOS and COX-2 in ALS transgenic mice and rat, even
preceding the development of clinical signs (Aimer et al., 2001; Elliott, 2001; 
Aimer et al., 2002; Weydt et al., 2002; Hensley et al., 2003; Xie et al., 2004). 
An increase expression of TNFR-1 and 2 was also revealed in the motor 
neurons of G93A transgenic mice already at the presymptomatic stage of the 
disease, and becomes particular evident also in the microglial cells at the 
endstage of the disease (Veglianese et al., 2006).
Recently, a series of studies revealed that the SOD1 mutations are probably not 
directly deleterious for motor neurons, but exert their neurotoxic effects in a 
‘non-cell autonomous’ mode involving non-neuronal cells in the degeneration 
of the motor neurons. Indeed, it was shown that neither neuronal nor astrocytic 
expression of the mutated SOD1 transgene is sufficient to produce motor neuron 
degeneration in mice (Gong et al., 2000; Pramatarova et al., 2001; Lino et al., 
2002). Furthermore, Clement et al. showed that in mutated SOD1 chimeric mice 
(mice with mosaic expression of the mutated SOD1 transgene) the severity of 
the ALS-phenotype depended on the proportion of CNS cells expressing the 
mutant transgene, but not on the cell type (i.e. neurons vs. nonneurons) 
(Clement et al., 2003). Individual motor neurons expressing mutated SOD1, but 
surrounded by non transgenic glia remained healthy, whereas non transgenic 
neurons bordered by mutant SOD1 expressing glia degenerated. This showed 
that mutated SOD1 expression in motor neurons is neither sufficient nor 
necessary to produce motor neuron degeneration.
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1.12.6 EXCITOTOXICITY
The condition referred as “excitotoxicity” was formulated for the first time by 
Olney (Olney, 1990). Experimental evidences have demonstrated that 
excitotoxicity could contribute to neuronal damage in a wide range of 
neurological disorders such as seizures, cerebral ischemia, head traumas, 
Alzheimer’s disease, Huntington’s chorea and AIDS encephalopathy, including 
ALS. Furthermore, it was demonstrated that specific forms of motor neuron 
disease are caused by oral intake of excitotoxins. For instance, consumption of 
mussels containing Domoic acid led to neurological symptoms such as 
headache, seizures, hemiparesis and motor neuronopathy (Teitelbaum et al., 
1990). The excitotoxin BOAA (p-N-oxalyl-amino-L-alanine), a potent AMPA 
receptor agonist present in the pea Lathyrus sativus caused lathyrism, an upper 
motor neuron disease characterized by spasticity (Spencer et al., 1986; Bridges 
et al., 1989). In addition, intrathecal injections with BOAA induced motor 
neuron degeneration in rat and mouse spinal cord (Chase et al., 1985). Another 
excitotoxin, BMAA (P-methylamino-L-alanine), present in the seeds of Cycas 
circinalis lead to Western Pacific ALS-Parkinsonism dementia (Guam Island). 
It was demonstrated that BMAA is an NMDA and AMPA receptor agonist 
(Copani et al., 1991).
Glutamate is the major excitatory amino acid of the central nervous system 
(CNS) which functions as a chemical signal in nervous conduction. It is located 
predominantly in the presynaptic vesicles that release glutamate in the cleft 
through a calcium dependent mechanism. When released, glutamate binds to 
receptors which are either ionotropic or metabotropic.
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Ionotropic receptors are the AMPA, NMDA and Kainate receptors forming 
ionic channels, while the metabotropic receptors are linked to G proteins that 
transduce the signal into the cytoplasm. One of the main mechanisms of 
glutamate inactivation is its re-uptake into astrocytes, where it is metabolized to 
a-ketoglutarate or converted to glutamine by glutamine synthetase.
Two types of excitotoxicity are distinguished: a classical excitotoxicity that 
occurs after an acute increase of the extracellular glutamate concentration 
(extracellular concentration of 2-5 pM is sufficient to cause degenerations of 
neurons) and is thought to induce damage in conditions such as stroke, status 
epilepticus and neurotrauma; while slow excitotoxicity characterized by a 
chronic and milder elevation of glutamate are believed to underlie excitotoxicity 
in neurodegenerative diseases (Van Den Bosch et al., 2006). An increased 
concentration of glutamate in the extracellular cleft can occur through an 
augmented release from presynaptic terminals or when the reuptake from the 
synaptic cleft through the glutamate transporter (EAAT2/GLT-1) located in the 
astrocytes is insufficient. Elevated concentrations of glutamate can also be 
released from injured neurons. Increased levels of glutamate in the synaptic 
cleft determine an excessive influx of calcium through the over-stimulation of 
its own receptors, both NMDA and AMPA. Furthermore, an augmented 
activation of kainate receptors is able to lead to the release of calcium from the 
endoplasmic reticulum (Pellegrini-Giampietro et al., 1997). Different 
mechanisms can be adopted by the cell to control the intracellular levels of 
calcium, such as pumping it outside, driving it into intracellular compartments 
that function as calcium sinks (i.e. mitochondria and endoplasmic reticulum), or 
providing proteins able to bind it (i.e.,parvalbumin and calbindin) (Heath and 
Shaw, 2002; Arundine and Tymianski, 2003). A deregulated homeostasis of
these defense systems may cause excessive intracellular calcium ion 
concentration that leads to the activation of cell death pathways. For example, 
increased levels of calcium in the cytoplasm activates protein kinases, 
phospholipases, and nitric oxide synthase and produces free radicals which 
destroy plasma membrane lipids, DNA and proteins (Orrenius and Nicotera,
1994). Furthermore, an excessive cytosolic calcium level may induce activation 
of the MPTP, with consequent osmotic changes and membrane swelling. This 
may be the initial step of the cascade of events leading to a failure of the ATP 
synthesis, reducing the energy available to maintain the physiologic 
concentration of calcium in the cytoplasm and creating a vicious circle.
For many years the main protagonist associated with events of excitotoxicity 
was the NMDA receptor, which was considered the only channel able to 
increase the calcium concentration in cells. Recently another receptor has been 
demonstrated to be important in the regulation of the calcium entry, particularly 
during chronic exposure to glutamate, namely the AMPA receptor. In a 
physiologic state a positively arginine residue in the GluR2 subunit makes the 
AMPA receptors impermeable to calcium entry, whereas an unedited form of 
this subunits, with a glutamine in the place of the arginine, makes the receptor 
permeable to calcium, and therefore able to trigger excitotoxic events.
Several experiments both in vivo and in vitro have demonstrated a selective 
vulnerability of motor neurons mediated by AMPA receptors. Intrathecal or 
intraspinal administration of AMPA receptor agonists induced motor neuron 
degeneration in animals, but this was not seen with an NMDA agonist 
(Pisharodi and Nauta, 1985; Hugon et al., 1989; Urea and Urea, 1990; 
Nakamura et al., 1994; Ikonomidou et al., 1996; Kruman et al., 1999). 
Organotypic rat spinal cord motor neurons cultures were vulnerable to AMPA
receptor mediated excitotoxicity, which could be prevented by antagonists 
(Rothstein et al., 1993; Saroff et al., 2000). A similar result has been obtained 
with motor neurons in culture when stimulated with AMPA agonist (Estevez et 
al., 1995; Urushitani et al., 1998; Vandenberghe et al., 1998; Fryer et al., 1999; 
Van Den Bosch and Robberecht, 2000). However, other neurons were resistant 
to AMPA stimulation (Van Den Bosch et al., 2000). To explain this selectivity 
different hypotheses were formulated, such as low levels of Ca buffering 
proteins (Celio, 1990; Ince et al., 1993; Alexianu et al., 1994). This condition 
leads the mitochondria to have a more important role in Ca buffering in motor
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neurons. Furthermore, motor neurons have a high proportion of Ca permeable 
AMPA receptors (Carriedo et al., 1996; Van Den Bosch et al., 2000), and it was 
demonstrated that the Ca2+ entry via Ca2+ permeable AMPA receptors is 
responsible for selective motor neuron death and this was confirmed also by 
AMPA antagonist (Van Den Bosch et al., 2000). Electrophysiological 
experiments have revealed a higher sensitivity to external polyamines, a lower 
rectification index and a higher relative Ca permeability ratio than other 
neurons, suggesting a deficiency in GluR2 subunits (Van Damme et al., 2002). 
The excitotoxic hypothesis proposed for ALS arises from several studies 
indicating a disgregulated glutamate metabolism in ALS cases. The level of 
glutamate in the cerebrospinal fluid (CSF) (Rothstein et al., 1990; Shaw et al., 
1995b) and in the plasma of ALS patients (Plaitakis and Caroscio, 1987) was 
found to be significantly elevated, although other studies have not confirmed 
these evidences (Perry et al., 1990; Camu et al., 1993). Other groups have 
demonstrated instead a reduced level of glutamate in several brain regions and 
in the spinal cord of ALS patients (Perry et al., 1987). Furthermore, toxicity was 
detected when ALS CSF and plasma were used in culture of neurons (Roisen et
al., 1982; Couratier et al., 1993; Cid et al., 2003; Sen et al., 2005), although 
these data were not confirmed using motor neuron cultures (Iwasaki et al.,
1995).
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1.12.6.1 GLUTAMATE CLEARANCE HYPOTHESIS
The clearance of glutamate from the extracellular environment by transporter- 
mediated uptake is an important mechanism to manage the glutamate 
concentration in the synaptic space. Glutamate transporters are expressed by 
many cell types in central nervous system, including oligodendrocytes, 
microglia, astrocytes and neurons (Rothstein et al., 1994). Five types of high- 
affinity Na+-dependent glutamate transporters, designated EAAT1 (known as 
GLAST in rodents), EAAT2 (named GLT1 in rodents), EAAT3 (EAAC1 in 
rodents), EAAT4 and EAAT5, have been cloned since 1992 (Kanai and 
Hediger, 1992; Pines et al., 1992; Storck et al., 1992; Arriza et al., 1997). GLT- 
1 and GLAST are predominantly localized on astrocytes. GLT-1 is the most 
abundant glutamate transporter in the forebrain, with GLAST particularly 
expressed in the cerebellum. The majority of glutamate uptake is into astrocytes 
and is mediated by GLT-1 and GLAST, which are therefore considered the most 
important in removing glutamate from the synaptic cleft during normal 
neurotransmission (Rothstein et al., 1996; Danbolt, 2001). An alteration of the 
glutamate uptake capability in astrocytes was suggested to be the possible cause 
of excitotoxic motor neuron death in ALS. Any decrease of glutamate uptake by 
astrocytes can lead to an increase of synaptic glutamate concentration, to 
overstimulation of glutamate receptors and consequently to excitotoxic insults 
to motor neurons. Consistent with this hypothesis is a diminished glutamate 
transport by the astroglial glutamate transporter EAAT2/GLT1 detected in the 
brain and spinal cord of ALS patients (Rothstein et al., 1992; Shaw et al., 1994; 
Rothstein et al., 1995). Experiments on organotypic spinal cord with antisense 
oligonucleotides to EAAT2/GLT1 were demonstrated to induce motor neuron
death (Rothstein et al., 1996). A similar result was obtained when the 
oligonucleotides was injected by intraventricular administration (Rothstein et 
al., 1996). A decrease level of this transporter was also described in the ventral 
horn of SOD1G93A and SOD1G37R mice (Bruijn et al., 1997b; Bendotti et al., 
2001b) and in rat mutated in SOD1G93A (Howland et al., 2002). Whereas other 
studies showed no change in EAAT2/GLT1 transporter (Sasaki et al., 2001; 
Deitch et al., 2002). Noteworthy, is the oxidative damage of EAAT2/GLT1 
through the catalysis of H2O2 by mutant SOD1 revealed in vitro (Trotti et al., 
2001), suggesting a vulnerability of the glutamate trasporter to toxic effect of 
SOD1. Furthermore, crossbreeding EAAT2/GLT1 overexpressing mice with 
SOD1G93A mice delayed disease onset, but did not prolong survival (Guo et 
al., 2003). Recently a blinded screen of 1040 drugs has revealed a p-lactam 
antibiotic (Ceftriaxone) as a potent stimulator of EAAT2/GLT1 expression, and 
this was also confirmed in vivo (Rothstein et al., 2005). Mutant SOD1 mice 
treated with this antibiotic showed an increased lifespan of about 11% and 
prevented motor neuron degeneration and astrogliosis (Rothstein et al., 2005). 
Taken together these data indicate that a higher clearance of glutamate from the 
synaptic cleft can ameliorate the ALS pathology.
1.12.6.2 ROLE OF AMPA RECEPTORS
As described previously, it is quite well established that motor neurons are more 
susceptible than other spinal neurons to toxicity mediated by AMPA receptors. 
It was hypothesized that this selective vulnerability of motor neuron to AMPA 
activation, in respect to other spinal neurons, might result from differences in
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AMPA receptor subunit expression. For example, the presence of AMPA 
receptors lacking GluR2 or lacking edited GluR2 would confer an increased 
Ca2+ permeability, which in turn can lead to deleterious enhanced levels of 
intracellular calcium and cell death. A decrease of GluR2 and GluRl mRNA 
were found in spinal cord homogenate of ALS patients in comparison to 
controls (Virgo et al., 1996; Takuma et al., 1999). However, a more accurate 
experiment by real time PCR did not reveal differences in the levels of GluR2 
mRNA between ALS patients and control groups (Kawahara et al., 2003), 
whereas a lower GluR2 editing efficiency was found in spinal grey matter of 
ALS sporadic patients (Takuma et al., 1999). This phenomenon was 
subsequently confirmed in single motor neurons isolated by laser 
microdissection from ALS sporadic patients (Kawahara et al., 2004b).
This Q/R site editing in GluR2 occurs with virtually 100% efficiency in 
mammalian neurons from an embryonic stage throughout life. This editing is 
catalyzed transcriptionally by the enzyme adenosine deaminase acting on RNA 
type 2 (ADAR2) where a glutamine (Q) codon of GluR2 is substituted by an 
arginine (R) codon through the editing of adenosine (A) to inosine (I) in the 
RNA.
Therefore, AMPA receptors that contain at least one edited GluR2 subunit have 
low Ca2+ conductance, whereas those lacking a GluR2 subunit or containing an 
unedited GluR2 subunit are Ca2+ permeable.
A significant downregulation of the flop form of GluR2 in the flip/flop region (a 
small aminoacidic segment preceding the fourth transmembrane region that 
impart different pharmacological and kinetic properties encoded by mRNA 
splice variants) was also observed, suggesting the formation of slowly
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desensitizing AMPA receptors could be an important mechanism of increase 
calcium entrance (Tomiyama et al., 2002).
In contrats to ALS patients, no changes in GluR2 editing was found in 
SOD1G93A rats (Kawahara et al., 2006).
However, recent results from our group have shown a reduction in the GluR2 
subunit protein level in motor neurons of SOD1G93A mice already at the 
presymptomatic stage of the disease, suggesting a likely causal role in the 
mechanism of motor neuron death. Since the GluR2 mRNA levels were 
unchanged, it has been hypothesized that a post translational modification was 
involved in reducing the levels of this subunit (i.e. increased protein 
degradation) (Tortarolo et al., 2006).
In line with the hypothesis of a role of AMPA receptor in motor neuron 
degeneration, in vivo treatment of SOD1G93A mice with AMPA receptor 
antagonists RPR119990 (Canton et al., 2001), l,2,3,4-tetrahydro-6-nitro-2,3- 
dioxobenzoquinoxaline (NBQX) (Van Damme et al., 2003) and ZK187638 
(Tortarolo et al., 2006) prolong the lifespan of these mice respectively by 13%, 
10% and 11%. Moreover, blocking the carboxypeptidase II with 2-MPPA 
(necessary for the metabolism of glutamate) increased the survival of 
SOD1G93A mice (Ghadge et al., 2003)
All these data suggest that AMPA receptors can be crucially involved in the 
onset and the progression of the disease in SOD1 mutant mice. It is still unclear, 
however, how they can be regulated to determine the selective vulnerability of 
spinal motor neurons.
A tight regulation of the AMPA receptor trafficking by several proteins 
(Braithwaite et al., 2000; Ehlers, 2000; Luscher et al., 2000; Man et al., 2000; 
Turrigiano, 2000; Carroll et al., 2001) and phosphorylation of the AMPA
receptor subunits by several kinases (Matsuda et al., 1999; Chung et al., 2000; 
Boehm and Malinow, 2005) were recently characterized as a determining 
regulatory mechanism of AMPA receptor function. A possible deficiency of 
these mechanisms regulating the bidirectional trafficking of the AMPA subunits 
between the cytoplasm and the postsynaptic membrane, may represent 
important targets that if compromised may lead to motor neuron degeneration.
1.13 AIM OF THE STUDY
The aim of this thesis is to carry out a study that may allow us to understand 
further the mechanisms that trigger or contribute to the development of ALS 
pathology. In particular, I focussed attention on the characterization of the role 
of the AMPA receptor in the selective spinal motor neuron death in FALS mice.
Specific aims of this thesis are:
• To further define the selective changes of AMPA receptor subunits in the 
vulnerable spinal motor neurons of SOD1G93A mice retrogradely labelled with 
fluorogold injected into the hind limb muscles.
• To investigate whether an altered composition of the AMPA receptor subunits 
in the post-synaptic membrane, where they are functional active, and in the 
cytosol, where they are stored, might determine an early predisposition to the 
excitotoxicity.
• To study the phosphorylation state of the GluR2 subunit, the most important 
subunit able to regulate calcium entry into neuronal cells, in SOD1G93A mice 
as a further mechanism of regulation of the trafficking of this subunit between 
the membrane and cytosol.
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• To evaluate whether AMPA receptor trafficking proteins (ABP, PICK1 and 
NSF), which are able to regulate AMPA receptor subunit trafficking and 
degradation, are altered in their distribution and expression in SOD1G93A 
mice. This could explain a possible deregulated recycling of the AMPA 
receptor subunits previously analyzed.
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CHAPTER 2 
METHODS
2.1 ANIMALS
Procedures involving animals and their care were conducted in according to the 
institutional guidelines that are in compliance with national (D.L. no. 116, G.U. 
suppl. 40, Feb. 18,1992, Circolare No.8, G.U., 14 luglio 1994) and international 
laws and policies (EEC Council Directive 86/609, OJ L 358, 1 DEC. 12, 1987; 
NIH Guide for the Care and use of Laboratory Animals, U.S. National Research 
Council, 1996). The animals were housed under standard conditions (22 ± 1°C, 
60% relative humidity, 12 hour light/dark schedule), 3-4 per cage, with free 
access to food (Altromin, MT, Rieper) and water.
Transgenic mice, expressing about 20 copies of mutant human SOD1 with a Gly 
93 Ala substitution (SOD1G93A), were originally obtained from Jackson 
Laboratories (B6SJL-TgNSOD-l-G93A-lGur). Male SOD1G93A mice were 
repeatedly backcrossed with non transgenic female C57BL/6 mice obtaining 
transgenic mice on the homogeneous C57BL/6 genetic background. These mice 
develop the first signs of neuropathology at the motor neuronal level around one 
month of age while the first symptoms of muscular dysfunction appear around 
three months of age, with tremors and a progressive reduction in the extension 
reflex of the hind limbs, when the mice are raised by the tail. At about four 
months of age, the mice start to show a progressive muscular weakness, 
revealed by the increasing difficulty to stay on a rotating bar and by a reduction 
in stride length on an inclined ramp. At this stage, more than 50% of motor 
neurons of the lumbar spinal cord are lost and two month later these mice die 
(Ciavarro et al, 2003).
Mitochondrial vacuolisation and the swelling of motor neurons are among the 
earliest events and are accompanied by a decreased function of the mitochondria
(Bendotti et al., 2001). Later, but still at the asymptomatic stage, the 
SOD1G93A mice show signs of cytoskeletal disorganization in the motor 
neurons, with the accumulation of phosphorylated neurofilaments in the 
perykaria (Tortarolo et al., 2003). The accumulation of detergent-insoluble 
proteins and ubiquitinated intracellular inclusions are particularly evident at 
advanced stages of the disease (Cheroni et al., 2005). Reactive gliosis, which 
involves hypertrophy and the activation of astrocytes and the proliferation and 
activation of microglia, is detectable with the degeneration of motor neurons 
and becomes prominent when the cell loss is remarkable (Veglianese et al., 
2006; Tortarolo et al., 2003). Hypertrophic astrocytes and reactive microglia are 
usually located around degenerating motor neurons.
For the present study female mice have been killed at 12, 18 and 23 weeks of 
age corresponding respectively to presymptomatic, early symptomatic and 
advanced stage of the motor dysfunction progression. Age-matched non 
transgenic littermates were used as controls.
2.2 IMMUNOHISTOCHEMISTRY
In this thesis fluorescence microscopy was used for a qualitative, but not 
quantitative, characterization of the distribution and expression of the AMPA 
receptor subunits and their trafficking proteins. Indeed, the quantification of 
fluorescence intensity is usually complicated by a variety of optical, biological, 
and physical factors. Another approach was considered to evaluate quantitatively 
these proteins, i.e. western blotting of the spinal cord described in section 2.3.
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2.2.1 GENERAL PROCEDURE
Mice were anaesthetised with Equithesin (1% phenobarbitol / 4% (vol / vol) 
chloral hydrate, 30 pi /10 g, ip.) and transcardially perfused with 20 ml saline 
followed by 50 ml of sodium phosphate buffered 4% paraformaldehyde 
solution. Spinal cords were removed, post fixed in fixative for two hours, 
transferred to 20% sucrose solution in PBS overnight, then in 30% sucrose 
solution until they sank. Finally spinal cords were frozen in 2-methylbutane at - 
45°C and conserved at -80° until the experiments. Fixed and frozen lumbar 
spinal cords of transgenic and non transgenic mice were cut on a cryostat at - 
20°C to obtain coronal sections of 30 pm at the L2-L4 levels. The lumbar tract 
of the cord was chosen because the hind legs of these mice are affected earlier 
and more severely compared to the forelegs.
2.2.1.1 Indirect immunofluorescence
Free-floating sections were treated with a blocking solution composed of 
normal goat serum (NGS), Triton X-100 at appropriate concentration to 
permeabilize the membrane and PBS 0.01 M for 1 hour. Subsequently, the 
sections were washed and treated with a first antibody solution containing 
antibodies at appropriate concentration with NGS 10%, Triton at different 
concentration and PBS; all kept under mild agitation overnight at 4°C. Then the 
sections were treated with a fluorescence secondary antibody (1:500) directed to
different species (mouse, rabbit and rat) and conjugated to fluorochromes with 
different wavelengths (ALEXA 488, 546 and 647, Molecular Probes, 
Invitrogen) in NGS 1% and PBS for 1 hour and mounted with Fluorsave 
(Calbiochem).
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2.2.1.2 Amplified immunofluorescence by Tyramide
Free-floating sections were first treated with H2O2 1% in PBS 0.01 M for 10 
minutes. Then, they were incubated in 10% NGS, Triton X-100 at appropriate 
concentration in PBS 0.01 M, for 1 hour and kept overnight at 4°C in the 
primary antibody solution at appropriate concentration containing 1% NGS and 
PBS. The following day, after three washes in PBS 0.01 M, sections were 
incubated with biotinylated secondary antibody (1:200, Vectastain kit, Vector 
Laboratories, Burlingame, CA, US) for 1 hour, washed with TNT (TBS 0.1 M; 
Triton 0.05%) and incubated with TNB (TBS 0.1 M, Blocking reagent 0.5%). 
Subsequently, the sections were again washed with TNT and treated with 
streptavidin (1:100, Perkin Elmer, NEN) in TNB for 30 minutes, washed with 
TNT and incubated for 10 minutes with Tyramide coniugated with Cy5 
fluorochrome (1:500, Perkin Elmer, NEN) in amplification diluent provided by 
the kit. The amplification technique was utilized to detect faint signal or reveal 
two antibodies of the same specie on the same section, taking advantage of the 
sensibility of this technique for one of the antibodies.
2.2.1.3 Fluorogold
Fluorogold solution (FG) (a retrograde tracer that labels motor neurons 
following intramuscular injection, Fluorochrome) was injected in two site for 
both medial and lateral gastrocnemius muscle (5 pl/site with a 1% FG diluted in 
water) according to Zhang et al. (Zang da, Lopes et al. 2005). After 5 days, 5
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control and transgenic mice at the presymptomatic stage of the disease were 
anesthetised with Equithesin (1% phenobarbitol / 4% vol / vol/ chloral hydrate, 
30 pi /10 g, ip.) and transcardially perfused with 20 ml saline followed by 50 ml 
of sodium phosphate buffered 4% paraformaldehyde solution. Spinal cords were 
removed, post fixed in fixative for two hours, transferred to 20% sucrose 
solution in PBS overnight, then in 30% sucrose solution until they sank. Finally 
spinal cords were frozen in 2-methylbutane at -45 °C and conserved at -80° until 
the experiments. Fixed and frozen lumbar spinal cords of transgenic and non 
transgenic mice were cut on a cryostat at -20°C to obtain coronal sections of 30 
pm at the L2-L4 levels.
Subsequently, on the sections FG was detected by immunofluorescence with the 
following procedure: free-floating sections were treated with a blocking solution 
composed of 10% NGS, 0.1% Triton X-100 and PBS 0.01 M for 1 hour. Then, 
the sections were washed and treated with a first antibody solution containing 
rabbit anti FG (1:1000) with NGS 10%, 0.1% Triton and PBS; all keep in 
shacking overnight at 4°C. After, the sections were treated with a fluorescence 
anti rabbit secondary antibody ALEXA 488 (1:500, Molecular probes, 
Invitrogen) in NGS 1% for 1 hour and mounted with fluorsave (Calbiochem).
2.2.2 IMMUNOFLUORESCENCE ANALYSIS OF GLUTAMATE AMPA 
RECEPTOR SUBUNITS
Immunohistochemical analysis was performed as described in section 2.2.1. 
Fixed lumbar spinal cords of SOD1G93A mice at 12, 18 and 23 weeks of age, 
corresponding to presymptomatic, symptomatic and end stage of the disease,
and non transgenic mice at the same age used as control (5 mice each group) 
were utilized.
The primary antibodies used were: rabbit polyclonal anti-GluRl, (1:100, 
Chemicon International, Harrow, UK), or mouse monoclonal anti-GluR2, 
(1:100, Chemicon International, Harrow, UK), or rabbit polyclonal anti-GluR2 
serine 880 phoshorylated, (1:100, Upstate) or mouse monoclonal anti-GluR3 
(1:100, Chemicon International, Harrow, UK) or rabbit polyclonal anti-GluR4 
(1:100, Chemicon International, Harrow, UK), diluted in PBS 0.01M additioned 
with 10% NGS and 0.1% Triton X-100. Biotinylated anti mouse or anti rabbit 
secondary antibody was used. Subsequently, the signal was amplified with the 
Tyramide amplification procedure described in section 2.2.1.2. A second 
staining, at the presymptomatic stage of the disease, was carried out using a 
rabbit antibody directed to FG revealed by an anti rabbit secondary antibody 
conjugated to Alexa 488 as previously described in the section 2.2.1.3. At the 
symptomatic and end stage of the disease, a second staining using a rat 
monoclonal antibody directed to CDllb, a microglia marker (1:1000, produced 
by the Immunology laboratories in Mario Negri Institute), and a third staining 
using a mouse monoclonal antibody directed to GFAP, an astrocyte marker 
(1:1000, Chemicon International, Harrow, UK), were carried out by indirect 
immunofluorescence described in section 2.2.1.1. The secondary antibodies 
used were respectively an anti rat antibody conjugated to ALEXA 488 and anti 
mouse conjugated to ALEXA 546.
Controls for the specific signal analyzed was carried out with the procedure 
above mentioned, but omitting the first antibody. A lack of signal was obtained 
on the sections demonstrating specific signal for each staining.
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Furthermore, a control of lack of cross signal using two primary antibodies of the same 
species on the same section was carried out. Because some of these antibodies are 
reised in a single species (GluRl,4 and FG), simultaneous immunoflourescent detection 
of multiple epitopes has been difficult. I have taken advantage of the high sensitivity of 
tyramide signal amplification for a protocol that permits simultaneous detection of two 
antibodies raised in the same species. One primary antibody was applied at a 
concentration below the detection limit of fluorescently labeled secondary antibodies, 
yet sufficient for detection with tyramide amplification (antibody ditected to GluRl or 
4). Whereas the antibody directed to FG have been detected by conventional 
immunofluorescence with a secondary antibody conjugated to ALEXA 488.
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2.2.3 IMMUNOFLUORESCENCE ANALYSIS OF GLUTAMATE AMPA 
RECEPTOR TRAFFICKING PROTEINS
Immunohistochemical analysis was performed as described in section 2.2.1. 
Fixed lumbar spinal cords of SOD1G93A mice at 12, 18 and 23 weeks of age, 
corresponding to presymptomatic, symptomatic and end stage of the disease, 
and non transgenic mice at the same age used as control (5 mice each group) 
were utilized. The primary antibodies used were: rabbit polyclonal anti-ABP, 
(1:500, Chemicon International, Harrow, UK) or rabbit polyclonal anti-PICKl, 
(1:500, Abeam, Cambridge, UK) or rabbit polyclonal anti-NSF (1:500, 
Chemicon International), diluted in PBS 0.01M additioned with 10% NGS and 
0.1% Triton X-100. Biotinylated anti rabbit secondary antibody was used. 
Subsequently, the signal was amplified with the Tyramide amplification 
procedure described in section 2.2.1.2.
A second staining at the presymptomatic stage of the disease was carried out 
with motor neurons marker (Fluorogold) as previously described in section 
2.2.1.3. For the end stage of the disease, a second staining with a mouse 
monoclonal antibody directed to GFAP, an astrocytes marker (1:1000, 
Chemicon International, Harrow, UK), was carried out only for the slices 
stained for NSF by an indirect immunofluorescence described in section 2.2.1.1. 
The secondary antibody to reveal the astrocytes was an anti mouse conjugated 
to ALEXA 488.
Also in this case, such as for the AMPA receptors subunits, the controls for the 
specific signal analyzed were carried out with the procedure above mentionated, 
but omitting the first antibody. A lack of signal was obtained on the sections 
demonstrating specific signal for each staining. Furthermore, no cross signal in
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the the study of colocalization of ABP, or PICK1 or NSF and FG (all antibodies 
made in rabbit) was obtained testing which is the dilution of the primary 
antibody directed to the AMPA receptor trafficking proteins detectable by 
tyramide, but below the threshold revealable by conventional secondary anti 
rabbit IgG conjugated with ALEXA 488 used to stain FG.
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2.2.4 CONFOCAL ANALYSIS
The signals obtained were acquired with OLYMPUS Confocal System 
(FLUOVIEW 500) using three lasers: Ar with a 488 nm emission line, to 
acquire Alexa 488 signal, He-Ne green laser with a 546 emission line, to acquire 
Alexa 546 signal and He-Ne red laser with a 647 emission line, to acquire Cy5 
signal. Analysis in double or triple staining was made by sequential scanning in 
order to avoid cross talk between the channels. Furthermore, a correct set up of 
pinholes was adopted for each wavelengths and magnification.
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2.3 WESTERN BLOTTING
2.3.1 GENERAL PROCEDURE
Mice were killed by decapitation and the spinal cord and brain were rapidly 
removed and separated in lumbar, cervical and thoracic spinal cord. The lumbar 
spinal cord segment was longitudinally laid with his dorsal portion on a support 
of the OCT (mounting medium that solidify at -20°C), the ventral portion 
remaining superficial. The OCT included spinal cord segment was then placed 
in a cryostat with the ventral portion facing up. The ventral portion was then cut 
longitudinally in 50 pm thick sections until the appearance of the ependimal 
channel as limit between the ventral and dorsal portion. The sections from 
ventral or dorsal portion of the spinal cord were collected in an eppendorf tube 
and immediately frozen.
2.3.1.1 Western blot of total homogenate of the ventral and dorsal portion
Frozen ventral and dorsal spinal cords of transgenic and no transgenic mice 
were sonicated in boiling lysis buffer (20 mM Tris/HCl, pH 7.5, 10% SDS) and 
centrifuged at 13000 rpm for 3 minutes at 4°C.
113
2.3.1.2 Western blot of subcellular fractions of the ventral and dorsal 
portion
Sections of ventral and dorsal portion cut longitudinally in 50 pm thick sections 
as above described of transgenic and no transgenic mice were washed with PBS 
0.01 M to eliminate trace of OCT from the preparation.
Subsequently, ventral and dorsal portion of the lumbar spinal cord were 
homogenized in buffered sucrose (320 mM sucrose, 2 mM DTT, 1 mM EGTA, 
1 mM EDTA, 4 mM HEPES-KOH, pH 7.4) supplemented with protease 
inhibitors in a glass-glass homogenizer. Cell debris and nuclei (PI) were 
removed by centrifugation for 10 min at 1.1 OOg. Then, the postnuclear 
supernatant (SI) was centrifuged for 10 min at 9.200g, and the resulting pellet 
was resuspended in the buffered sucrose (320 mM sucrose, 2 mM DTT, 1 mM 
EGTA, 1 mM EDTA, 4 mM HEPES-KOH, pH 7.4). The resuspended pellet was 
further centrifuged for 15 min at 10.200g to obtain the washed synaptosomal 
fraction (P2). Supernatant from the medium-speed centrifugation was 
centrifuged for 2 h at 167.000g to obtain microsomal pellet (P3) and soluble 
protein fraction (S3). The washed P2 was lysed by addition of 10 volumes of 
water and the synaptosomal membrane-enriched fraction (LP1) was collected by 
centrifugation at 25.000g for 20 min (Lee, Valtschanoff et al. 2001).
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2.3.1.3 Immunoblot
Ventral and dorsal total homogenates or their subcellullar fractionation are 
subsequently characterized for the protein concentrations by using a BCA 
Protein Assay Reagent Kit (Pierce, Rockford,IL,US A). Samples were then 
boiled for 3 minutes in loading buffer (100 mM Tris/HCl, pH 7.5, 15% a- 
mercaptoethanol, 4% SDS; 15% glycerol, 5 mM EGTA, 5 mM EDTA, 0,2% 
bromophenol blue) and run on polyacrylamide-SDS gel and transferred to 
nitrocellulose membrane (Scheicher and Schuell, Keene, NH, USA). 
Membranes were incubated in blocking buffer made of TBST (20 mM 
Tris/HCl, 150 mM NaCl, 0.05% Tween-20) with 5% skimmed milk for 1 hours 
at room temperature, followed by incubation overnight at 4°C with primary 
antibody diluted in TBST with 5% bovine serum albumin or skimmed milk. The 
blots were then washed three times in TBST and incubated with secondary 
antibody in TBST with 5% skimmed dry milk, for 1 hour at room temperature. 
Blots were then developed by the ECL technique (Amersham Biosciences) 
according to the manufacturer’s instructions. Densitometric analysis of 
autoradiographic bands was done using a computer-assisted image analysis 
system (AIS 3.0, Imaging Research Inc.).
The quantitative evaluation of AMPA receptor subunits was expressed in 
relation to the level of actin as constitutive protein in the total homogenate, 
whereas a ratio between the optical density of the band specific for each subunit 
and that corresponding to PSD95 or GM130 from the same blot was carried out 
respectively for the LP1 and P3 fraction. A preliminary analysis was carried out 
demonstrating no changes in PSD95 and GM130 expression in transgenic mice 
compared to controls.
The level of purity of the two fractions was evaluated by the selective presence 
of PSD95 in post synaptic density contained in the LP1, but not in P3 fraction, 
and vice versa by the presence of GM130 exclusively in the P3, cytosolic 
fraction, but not in LP1 fraction.
As an internal control for each animal, I considered the ratio between the levels 
in ventral horn versus the dorsal horn in both transgenic and non transgenic 
mice.
Statistical analysis was performed using Mann-Whitney test (GraphPad Prism 
2.0a for Power Macintosh, GraphPad Software Inc.).
2.3.2 WESTERN BLOT ANALYSIS OF GLUTAMATE AMPA 
RECEPTOR SUBUNITS IN SUBCELLULAR FRACTIONS OF 
LUMBAR SPINAL CORD
Western blot analysis was performed as described in section 2.3.1.2. Frozen 
spinal cords of SOD1G93A mice at presymptomatic stage of the disease and 
control mice at the same age (7 mice each group) were used. Thirty |ig 
protein/lane of each sample were run on polyacrylamide-SDS gradient gel (7%) 
(Bio-Rad laboratorie, Hercules, CA, USA). The primary antibodies used were: 
polyclonal mouse anti-GluRl (1:250, Chemicon International, Harrow, UK) or 
monoclonal mouse anti-GluR2 (1:500, Chemicon International, Harrow, UK) or 
monoclonal mouse anti-GluR3 (1:2000, Chemicon International, Harrow, UK) 
or polyclonal mouse anti-GluR4 (1:250, Chemicon International, Harrow, UK) 
or polyclonal mouse anti Post Synaptic Density protein 95 (PSD95) (1:500, 
made in Prof.Carlo Sala’s laboratory, CNR, Milan) or monoclonal mouse anti- 
GM130, a protein that plays a role in the stacking of Golgi cistemae,
maintaining cis-Golgi structure and in vesicular transport, (1:500, BD 
Bioscience). Anti-mouse or anti rabbit IgG conjugated to horseradish 
peroxidase (1:2000, Sigma, Poole, UK) were used as secondary antibody. Blots 
were developed using ECL plus Western Blotting Detection System (Amersham 
Biosciences) according to the manufacturer’s instructions.
2.3.3 WESTERN BLOT ANALYSIS OF GLUTAMATE AMPA 
RECEPTOR TRAFFICKING PROTEINS IN TOTAL HOMOGENATE 
OR SUBCELLULAR FRACTIONS OF LUMBAR SPINAL CORD
Western blot analysis was performed as described in section 2.3.1.1-2.3.1.2. 
Frozen spinal cords of SOD1G93A mice at presymptomatic stage of the disease 
and control mice at the same age (7 mice each group) were used. Eighty (total 
homogenate) or thirty (subcellular fractionation) ng protein/lane of each sample 
were run on polyacrylamide-SDS gradient gel (7%) (Bio-Rad laboratorie, 
Hercules, CA, USA). The primary antibodies used were: polyclonal rabbit anti- 
ABP (1:250, Chemicon International, Harrow, UK) or polyclonal rabbit anti- 
PICK1 (1:500, AbCAM, Cambridge, UK) or polyclonal rabbit anti-NSF (1:500, 
Chemicon International, Harrow, UK) or monoclonal mouse anti-Actin (1:250, 
Chemicon International, Harrow, UK) or polyclonal rabbit anti-PSD95 (1:500, 
Post Synaptic Density protein 95, made in Prof.Carlo Sala’s laboratory, CNR, 
Milan) or monoclonal mouse anti-GM130 (1:500, a protein that plays roles in 
the stacking of Golgi cistemae, maintaining cis-Golgi structure and in vescicular 
transport., BD Bioscience). Anti-mouse or antirabbit IgG conjugated to 
horseradish peroxidase (1:2000, Sigma, Poole, UK) was used as secondary
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antibody. Blots were developed using ECL plus Western Blotting Detection 
System (Amersham Biosciences) according to the manufacturer’s instructions.
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CHAPTER 3
Study of the expression of glutamate AMPA 
receptor subunits in the spinal cord of 
SOD1G93A mice during the progression of
the disease
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3.1 EXPRESSION AND DISTRIBUTION OF AMPA 
RECEPTOR SUBUNIT PROTEINS IN THE MOTOR 
NEURONS OF SOD1G93A MICE DURING THE 
PROGRESSION OF THE DISEASE EXAMINED BY 
IMMUNOFLUORESCENCE ANALYSIS
3.1.1 HYPOTHESIS AND AIM
Previous results from my laboratory have demonstrated by western blot and 
immunohistochemistry a decreased level of the GluR2 subunit in the ventral 
horn of SOD1G93A mice at the presymptomatic stage of the disease (Tortarolo 
et al., 2006).
The aim of this study is to further characterize the expression of the different 
AMPA receptor subunits selectively in the motor neurons of presymptomatic 
SOD1G93A mice. Motor neurons are specifically identified using fluorogold, a 
retrograde tracer injected at different sites of the gastrocnemius muscle. The 
distribution and expression of these subunits will be analyzed also during the 
progression of the disease. Moreover, I evaluate whether possible changes of 
post translational phosphorylation of the GluR2 subunit (GluR2-P), which is 
responsible for the removal of GluR2 from the postsynaptic membrane, may 
contribute to the development of the pathology.
120
3.1.2 RESULTS
3.1.2.1 Analysis of the expression and distribution of the AMPA receptor 
subunits in the motor neurons of SOD1G93A at the presymptomatic stage 
of the disease
Immunolabelling for AMPA receptor subunits was performed in the lumbar 
spinal cord of presymptomatic SOD1G93A mice compared to non transgenic 
mice.
Each subunit of AMPA receptors (GluRl-4) was analyzed in association with 
FG staining of motor neurons.
Fluorogold staining:
FG labelling showed a selective intense fluorescence in the motor neurons of 
the lamina IX of the ventral horn of the lumbar spinal cord, whereas no staining 
was observed in the dorsal horn (Fig 3, a). Motor neurons show a diffuse 
staining in perikarya and dendrites (Fig 3, b). The mechanism of transport of the 
FG from the neuromuscular junction to the cytosol of the motor neurons is not 
weel characterized. However an active retrograde transport has been proposed. 
A limit of this FG could be the capacity to reach a different number of the motor 
neurons given that an altered axonal transport has been demonstrated in the 
G93A compared to CTR mouse. Hence, a preliminar study comparing the 
number of the motor neurons stained with FG for both CTR and G93A at the 
presymptomatic stage of the disease has been carried out demonstrating a
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comparable capacity to stain the same number of the motor neurons at this stage 
of the disease analyzed.
GluRl staining:
A diffuse staining for GluRl subunits was evident in the spinal cord of control 
mice with an intense signal in the cells of the dorsal horn (substantia gelatinosa) 
and some scattered signal detectable in the ventral horn (Fig 3.1, A; a,b). At 
high magnification, the most intense staining was detected in both motor neuron 
perikarya and dendrites (Fig 3.1, A; c-d arrows). Some motor neurons of 
SOD1G93A mice stained with FG showed a massive vacuolization (Fig 3.1, A; 
g,h), however, no apparent changes in the expression of GluRl subunits was 
evident in these cells comparing the intensity of colocalization signal of GluRl 
and FG between control and transgenic mice (Fig 3.1, A; e,f,g,h). No 
differences was found also in the neuronal cells of the dorsal horn of the 
transgenic mice (Fig 3.1, A; a,b,e,f).
GluR2 staining:
Analysis of GluR2 showed a pattern of distribution similar to GluRl in control 
mice with a staining in the neuronal cells of the ventral horn and in the dorsal 
horn. However, a much more intense signal of this subunit was specifically 
distributed in motor neuron cells stained with FG (Fig 3B, a-d). Unlike the 
GluRl, in transgenic mice at the presymptomatic stage of the disease, a
decreased staining was observed selectively in the cytoplasm of the motor 
neurons, but not in other neuronal cells. This appeared evident from a decreased 
colocalization with FG staining in SOD1G93A mice in respect to non transgenic 
controls (Fig 3.1, B; g,h arrow). It was also interesting to note that a decreased 
level of GluR2 was detected in motor neurons without apparent signs of 
degeneration (vacuolisation or morphological alteration) suggesting an early 
event in the motor neuron degeneration (Fig 3.1, B; g,h arrow). This further 
confirms that the decrease of this subunit occurs selectively in the motor neuron 
cells.
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GluR3 staining:
GluR3 staining showed a pattern of distribution similar to GluRl and 2 in the 
dorsal and ventral horns of the control mice with an intense signal in the FG 
positive motor neurons (Fig 3.2, A; a-d). Analyzing the transgenic mice no 
differences was revealed neither in the ventral horn (motor neurons did not 
show changes of colocalization intensity between GluR3 and FG) nor in the 
dorsal horn (Fig 3.2, A; e-h).
GluR4 staining:
GluR4 showed a staining throughout the grey matter and a clear staining in the 
perikarya of the motor neurons in ventral horn of control mice stained with FG 
(Fig 3.2, B; a-d). Also in this case, as for GluR3 and GluRl, evaluating the 
transgenic mice no differences were detected at this stage of the disease in the 
ventral (no changes of colocalization intensity between GluR4 and FG) and in 
the dorsal horn compared to controls (Fig 3.2, B; e-h).
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3.1.2.2 Analysis of GluR2 phosphorylation in the motor neurons of 
SOD1G93A at the presymptomatic stage of the disease
GluR2-P staining:
In order to study weather a post translational event could influence the 
trafficking and the level of GluR2 in the motor neurons, an immunofluorescence 
analysis with an antibody directed to the phosphorylated form of GluR2 at the 
serine site 880 was carried out in control and transgenic mice. A diffuse staining 
was found in the control mice mostly localized in the ventral horn and in the 
substantia gelatinosa of the dorsal horn (Fig 3.3; b). In the ventral horn a strong 
signal was found in the motor neurons with an higher staining localized in 
proximity of the membrane (Fig 3.3; d,e ) suggesting a preferential localization 
of phosphorylated GluR2 in the postsynaptic membrane. Analyzing the 
transgenic mice at the presymptomatic stage of the disease, no significant 
changes was observed compared to control mice (Fig 3.3; b,c), although a 
reduced staining in few morphologically altered motor neurons was present (Fig
3.3, f, arrow).
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Fig 3: FG immunofluorescence in lumbar spinal cord of control mice
In control mice a selective Fluorogold (FG) immunoreactivity (green) is localized in 
the ventral horn o f the grey matter with a marked staining in a pool o f ventral horn 
motor neurons corresponding to the lamina IX (a). At high magnification FG 
immunostaining is distributed in the perikarya and dendrites o f the motor neurons (b). 
Scale bars: (a =  200 pm); (b= 50 pm).
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Fig 3.1: GluRl and GluR2 immunofluorescence in lumbar spinal cord of 
SOD1G93A mice at the presymptomatic stage of the disease
In control mice a widespread GluRl and GluR2 immunoreactivity (red) is localized 
throughout the whole grey matter with a marked staining in the dorsal horn and in 
motor neurons o f ventral horn (A,B; a,c;). In the motor neurons, stained by Fluorogold 
(FG, green), GluRl immunostaining is distributed in cell body and neurites (A; c, 
arrows). No significant changes in GluRl immunostaining are observed in the dorsal 
horn ofSOD!G93A mice (A; a,e), and in ventral horn (A; a,c,e,g), whereas, decreased
labelling is revealed in the ventral region fo r GluR2 (B; c,g, miniature). In particular, 
we could observe a decrease o f GluR2 immunostaining in the perikarya o f some the 
motor neurons (B; g, arrow). Scale bars: (A,B; a ,b ,e f  =  200 pm); (A,B; c,d,g,h= 50 
pm).
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Fig 3.2: GluR3 and GluR4 immunofluorescence in lumbar spinal cord of 
SOD1G93A mice at the presymptomatic stage of the disease
In control mice, a widespread GluR3 and GluR4 immunoreactivity (red) is localized 
throughout the whole grey matter with a marked staining in the dorsal horn and in 
motor neurons o f ventral horn (A,B; a,c). In the motor neurons, stained by Fluorogold 
(FG, green), GluR3 and GluR4 immunostaining is distributed in the perikarya and 
neurites (A,B; c). No significant changes in GluR3 and GluR4 immunostaining are
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observed in the ventral and dorsal horn o f SOD1G93A mice (A,B; a-h). Scale bars: 
(A,B; a ,b ,e f=  200 pm); (A,B; c,d,g,h= 50 jum).
Fig 3.3: GluR2-P immunofluorescence in lumbar spinal cord of SOD1G93A 
mice at the presymptomatic stage of the disease
A diffuse immunoreactivity o f phosphorylated GluR2 at the serine site 880 (GluRl - 
P,red) is localized throughout the whole grey matter with a marked staining in the 
dorsal horn and in motor neurons o f ventral horn o f  control mice (b,e). In the motor 
neurons a faint signal is present in the perikarya, whereas a more intense staining is 
localized in proximity o f the membrane (e) compared to GluR2 (d). No significant 
changes in GluR2-P immunostaining are observed in the ventral horn (e,J) and dorsal 
horn (b,c) o f SOD1G93A mice compared to control mice. Interesting some vacuolized 
motor neurons preserve a membrane staining o f the GluR2-P (f, arrow). Scale bars: 
(a,b,c =  200 pm); ( e f d =  50 pm).
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3.1.2.3 Analysis of the distribution and the expression of the AMPA 
receptor syubunits and GluR2-P during the progression of the disease, at 
symptomatic and final stage of the pathology
Subsequently, the distribution and expression of GluRl, 2, 3, 4 and GluR2-P 
were evaluated during the progression of the disease at symptomatic and end 
stage.
In order to characterize the non-neuronal staining, a study of colocalization in 
triple staining with markers for both the microglia cells (CDlib, green) and 
astrocytes (GFAP, blue) was performed as described above in section 2.2.1.1.
GluRl staining:
A scattered signal particularly evident in the ventral horn at the symptomatic 
stage (Fig 3.4, b) that becomes more diffuse in the whole grey matter at the final 
stage (Fig 3.4, c) was detected in the transgenic compared to control mice (Fig
3.4, a). A scattered GluRl signal was observed around the motor neurons at the 
symptomatic stage (Fig 3.5, b) and becomes more intense and diffuse at the 
endstage (Fig 3.5, c). The survived motor neuron cells did not show any 
differences at both the stages examined compared to control (Fig 3.5, a). A 
partial colocalization at symptomatic stage (Fig 3.6, B; f,g/3.10, A; b,c) and a 
more intense and diffuse colabeling at the endstage of the disease (Fig 3.6, B; 
j,k/3.10, B; b,c) was found with GFAP immunostaining which recognized 
hypertrophic astrocytes. No colocalization with the marker for activated 
microglial cells has been reported at all the stages of the disease examined (Fig
GluR2 staining:
Unlike for the presymptomatic mice that showed a decrease staining in few 
motor neurons, there were no clear differences in the GluR2 immunostaining in 
survived motor neurons at the symptomatic (Fig 3.5, e) and end stage (Fig 3.5, 
f) of the disease compared to control mice (Fig 3.5, d). Instead, with the 
progression of the disease an intense scattered signal was present around the 
motor neurons. Analyzing thoroughly such scattered signal in experiments of 
triple staining with markers for both microglia and astrocytes, a clear 
colocalization between GluR2 and marker of microglia has been detected at the 
symptomatic stage (Fig 3.7, B; f,h/3.10, A; e,f) and even more at the end stage 
the disease (Fig 3.7, B; j,1/3.10, B; e,f). No colocalization was found with GFAP 
labelled astrocytes (Fig 3.7, B; g,k,c).
GluR3 staining:
Also the GluR3 immunostaining appeared intense and scattered around the 
motor neurons at the symptomatic and end stage (Fig 3.4-3.5, g, h, i). 
Examining the colocalization of GluR3 with marker for astrocytes (GFAP) and 
microglia (CDlib), we observed an overlapping staining of scattered signal 
with CD lib , but not with GFAP at the symptomatic (Fig 3.8, B; f,g,h/3.10, A; 
h,i) and even more at the end stage of the disease (Fig 3.8, B; j,k,l/3.10, B; h,i). 
Survived motor neurons of SOD1G93A mice at both stages showed no 
difference in the GluR3 immunostaining in respect to controls (Fig 3.5, g, h, i).
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GIuR4 staining:
No changes of GluR4 staining in the reactive glial cells has been documented in 
the transgenic mice during the progression of the disease at the symptomatic 
(Fig 3.9, B; e-h) and end stage (Fig 3.9, B; i-1) of the disease, such as 
demonstrated by lack of colocalization between GluR4 and the markers for 
astrocytes (GFAP) and reactive microglial cells (CDllb). Furthermore, the 
staining of GluR4 in the survived motor neurons of the transgenic mice 
appeared not changed compared to control motor neurons (Fig 3.5; j-1).
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GluRl
Fig 3.4: GluRs immunofluorescence at the symptomatic and end stage of 
the disease in lumbar spinal cord of SOD1G93A mice (Low magnification)
A scattered immunoreactivity (red) is revealed in the ventral horn o f transgenic mice 
(b,e,h) at the symptomatic stage for GluRl,2 and 3 compared to control mice (a,d,g). At 
the endstage these diffuse staining become more pronounced and diffuse in the whole
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grey matter (c,fi). No differences between control (j) and transgenic is detected at both 
symptomatic and end stages o f the disease fo r GluR4 (k.l). Scale bars: (a-l = 200 pm).
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Fig 3.5: GluRs immunofluorescence at the symptomatic and end stage of 
the disease in lumbar spinal cord of SOD1G93A mice (High magnification)
A scattered staining is reported around the motor neurons for GluRl, 2 and 3 (b,e,h), 
but not for GluR4 (k). Whereas, no clear differences in intensity or distribution o f  the 
signal is present comparing motor neurons in control (a,d,g,j) and transgenic mice 
(b,e,h,k) for GluRl,2,3 and 4 at the symptomatic stage. At the endstage o f the disease, a
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reduced amount o f motor neurons is present with a predominant scattered staining for  
GluRl, 2 and 3 around them (c,fi), whereas GluR4 (I) in transgenic mice do not show 
difference with the control mice (j). Scale bars: (a-l =  200 pm).
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Fig 3.6: Study of colocalization of GluRl with glial cells at the symptomatic
and end stage of the disease in lumbar spinal cord of SOD1G93A mice
During the progression o f the disease an increase gliosis, represented by an augmented 
immunoreactivity for both markers fo r astrocytes (GFAP, blue) and microglial cells 
(CD 11b,green), is reported mostly in the ventral horn at the symptomatic stage (A; 
f,g,h,). At the endstage hypertrophic astrocytes and reactive microglia diffuse in the 
whole spinal cord (A; j,k,l). Analyzing GluRl signal (red), a scattered immunostaining 
is reported in the ventral horn at the symptomatic stage diffusing in the whole grey 
matter at the end stage (A; e,i). At high magnification, a study o f colocalization shows 
an increased staining o f GluRl exclusively in the hypertrophic astrocytes (violet) (B; 
f,j,g,k), but not in reactive microglial cells at symptomatic stage. A colocalization 
staining o f GluRl with the hypertrophic astrocytes is much more represented at the end 
stage o f the disease (B; f,j,h,l). Scale bars: (A; a,I =  200 pm); (B; a,l= 50 pm)
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Fig 3.7: Study of colocalization of GluR2 with glial cells at the symptomatic
and end stage of the disease in lumbar spinal cord of SOD1G93A mice
An increased diffuse immunoreactivity o f GluRl (red) is localized in the ventral horn o f 
the transgenic mice at the presymptomatic stage (A, e) compared to control mice (A, a). 
This signal becomes more diffuse and intense at the end stage o f the disease throughout 
the whole grey matter (A,i.).
Analyzing at high magnification the colocalization o f GluR2 with the glial cells, a 
colabeling exclusively with the microglia (CDllb, green) is present at the symptomatic 
stage o f the disease (B, fh )  that becomes more intense and diffuse at the end stage (B; 
j,l), whereas GluR2 is not present in astrocytes (GFAP, blue) (B; g,k) compared to 
control (B; c). Scale bars: (A; a,I =  200 pm); (B; a,l= 50 pm)
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Fig 3.8: Study of colocalization of GluR3 with glial cells at the symptomatic
and end stage of the disease in lumbar spinal cord of SOD1G93A mice
An increased diffuse staining o f GluR3 (red) is localized in the ventral horn o f the 
transgenic mice at the symptomatic stage (A, e), that becomes more intense and diffuse 
at the end stage o f the disease (A, i). Analyzing at high magnification the colocalization 
o f GluRS with the glial cells, a colabeling exclusively with the microglial cells (CDllb, 
green) is present at both the symptomatic (B; fh )  and end stage o f the disease (B; j,l), 
whereas no colocalization is present with astrocytes (GFAP, blue) at all the stages 
examined (B;g,k) compared to control (B,c). Scale bars: (A; a, I = 200 pm); (B; a,l= 50 
pm)
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Fig 3.9: Study of colocalization of GluR4 with glial cells in lumbar spinal
cord of SOD1G93A mice at the symptomatic and end stage of the disease
A GluR4 staining is distributed in the ventral and dorsal horn o f the spinal cord o f 
control mice (A, a-d). At high magnification a staining in the perikarya o f the motor 
neurons is revealed (B, a-d). Analyzing the transgenic mice no differences are observed 
in survived motor neurons and glial cells at both symptomatic (A,B, e-h) and endstage 
(A,B, i-l) o f the disease.
Scale bars: (A; a,I = 200 pm); (B; a,l= 50 pm)
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Fig 3.10: Study of colocalization of GluRs with glial cells in lumbar spinal 
cord of SOD1G93A mice at the symptomatic and end stage of the disease 
(high magnification)
High magnification o f the colocalization o f  GluRl and 2,3 respectively with 
hypertrophic astrocytes (GFAP, blue) and the microglial cells (C D lib, green) at both 
the symptomatic (A; b,c,e,fh,i) and end stage o f the disease (B; b,c,efh,i). Scale bars: 
(A,B, a-i =  20 pm)
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3.2 STUDY OF SUBCELLULAR DISTRIBUTION OF 
GLUTAMATE AMPA RECEPTOR SUBUNITS IN 
THE SPINAL CORD OF SOD1G93A MICE
3.2.1 HYPOTHESIS AND AIM
It was suggested that alterations in the postsynaptic membrane stoichiometry of 
AMPA receptor subunits lead to modification in synaptic efficacy of 
glutamatergic transmission which may be potently neurotoxic. In order to define 
if this phenomenon may contribute to the motor neuron death in ALS, in this 
part of the work I have examined the composition of AMPA receptor subunits 
in the postsynaptic membrane, in respect to the cytosol where the receptors are 
stored and ready to be carried to the postsynaptic membrane or addressed to the 
degradation. The analysis was carried out in lumbar spinal cord of SOD1G93A 
at the presymptomatic stage of the disease compared with non transgenic 
littermates.
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3.2.2 RESULTS
In order to evaluate an early alteration of the subcellular distribution of the 
AMPA receptor subunits, and the phosphorylated form of GluR2. This study 
investigated only the presymptomatic stage of the disease of the transgenic mice 
compared to age matched control mice. A further reason to evaluate only the 
presymptomatic stage is the attempt to relieve a possible alteration of these 
subunits selectively in the motor neurons. Indeed, the results reported in section
3.1 of this thesis have shown an alteration of these subunits also in the glial cells 
during the progression of the disease affecting quantitative estimation of the 
AMPA subunits in the motor neurons at other stages.
I have examined the ventral and the dorsal horn of the lumbar spinal cord 
separately as described above in section 2.3.1.2-2.3.2. Two fractions were 
analyzed, a cytosol fraction (P3) and a synaptosomal membrane enriched 
fraction (LP1) from the ventral and dorsal portion.
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GluRl subunit:
The amount of GluRl AMPA subunit protein expressed in the ventral and 
dorsal spinal cord of SOD1G93A mice was tested at the presymptomatic stage 
of the disease. Analyzing the two fractions, only a detectable band o f-100 KDa 
for GluRl in the LP1 has been revealed (Fig 3.11 A), whereas P3 has shown no 
detectable signal.
No significant differences in the level of GluRl in LP1 fraction were observed 
comparing the controls to transgenic mice (Fig 3.11 A).
GluR2 subunit:
An intense band of -100 KDa for GluR2 has been also detected in P3 fraction 
suggesting a redistribution of this subunit between the cytoplasm and the 
postsynaptic membrane (Fig 3.11C). Interestingly, whereas a quantitative 
determination of the optical density of the band of GluR2 in LP1 fraction did 
not reveal any significant change when comparing controls to transgenic mice, a 
significant decrease was detected in P3 fractions of transgenic animals (Fig 
3.11C).
149
GluR2-P subunit:
With the aim to define whether events of phosphorylation could alter expression 
or trafficking of the GluR2 subunit in postsynapse, the phosphorylated status of 
the GluR2 in LP1 fraction was analyzed. The result obtained has shown no 
changes between the quantitative evaluation of the specific bands of -100 KDa 
obtained in controls and transgenic mice (Fig 3.1 ID).
GluR3 subunit:
An intense band of -100 KDa was seen also for GluR3 subunit in both the 
fractions considered. However, contrary to the decreased expression of GluR2 
in the P3 fraction, Glu3 did not show any changes of band intensity between 
controls and transgenic mice in both analyzed fractions (Fig 3.1 IE).
GluR4 subunit:
As GluR3, an intense band of -100 KDa was seen for GluR4 subunit in both 
LP1 and P3. Also in this case, no significant change was detected when 
comparing control to transgenic mice (Fig 3.1 IF).
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Fig 3.11: Western blot analysis of the expression of AMPA receptor 
subunits in subcellur fractionation of ventral and dorsal spinal cord of 
SOD1G93A mice
Results show quantitative evaluation o f GluRl, GluRl, GluR2-P,GluR3 and GluR4 
(A,C-F) in the cytosol fraction (P3) and synaptosomal membrane enriched fraction 
(LP1) obtained from ventral (VH) and dorsal (DH) portion o f lumbar spinal cord o f 
SOD1G93A mice at the presymptomatic stage, and their non transgenic littermate. The 
protein levels are expressed as ratio between band intensity and the optical density o f 
each GluRs band compared to that PSD95 (B) in the same blot fo r the LP1 fraction, 
whereas as ratio with GM130 (B) for the P3 fraction; this to normalize a possible 
different loading. A ratio between the VH and DH portion fo r each fractions was 
carried out. No evident differences in GluRl, GluR2-P, GluR3 and GluR4 band 
intensity were observed in both the fractions LP1 and P3 in SOD1G93A mice at 
presymptomatic stage o f the disease when compared to controls at the same age (A,D- 
F). Whereas, a significant decrease in GluR2 band intensity was only found in the P3 
fraction o f transgenic mice compared to control (C). Each column shows the mean ±  
S.E.M (n=7). Data analysed by Mann Whitney test.
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3.3 DISCUSSION
Several data suggest that AMPA receptors can be involved in the onset and the 
progression of the disease in SOD1 mutant mice. Alterations of the molecular features 
and composition of AMPA receptors may result in aberrant glutamatergic transmission 
and increased calcium entry, which in turn can lead to cell death. It is still unclear, 
however, how they can be regulated to determine the selective vulnerability of spinal 
motor neurons.
In this part of the project I have demonstrated that the sciatic nerve pool of motor 
neurons in lumbar spinal cord selectively labelled by FG injected in the hind limb 
muscles of presymptomatic SOD1G93A mice show lower levels of the GluR2 AMPA 
subunit in respect to those of control mice. In particular here, I demonstrated that the 
reduction in GluR2 is specific for motor neurons because of its colocalization with FG, 
which label selectively the sciatic nerve pool of motor neurons, was remarkable 
reduced.
In line with these data, we also found a decrease of GluR2 by western blot, but only at 
the level of the cytosol. The fact that these alterations were observed in mice at the 
presymptomatic stage of the disease, suggests that this event may have a causative role 
in triggering the pathology in these mice.
Previous data from our lab showed no changes of GluR2 mRNA in the motor neurons 
of presymptomatic SOD1G93A mice, demonstrating that reduced level of GluR2 
protein is not related to a decreased synthesis (Tortarolo, Grignaschi et al. 2006). This 
indicates that a post translational event can lead to decrease of GluR2 protein 
expression in the lumbar motor neurons of SOD1G93A mice.
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AMPA receptors cycle rapidly between intracellular and plasma membranes and the 
amount of internalized receptor are strongly affected by the rate of recycling to the 
surface as well as by the rate of endocytosis (Ehlers 2000; Lee, Simonetta et al. 2004). 
It was demonstrated that a rapid loss of synaptic AMPA receptors occurred following 
synaptic stimulation with subsequent induction of long-term depression (LTD) (Carroll, 
Lissin et al. 1999) or with exogenous application of glutamate (Lissin, Carroll et al. 
1999). Furthermore, experiments carried out in neuronal culture have demonstrated that 
AMPA receptors activation causes a Ca2+-independent internalization of AMPARs, 
which are then targeted to endosomes and degraded by lysosomes (Ehlers 2000). After 
endocytosis, AMPA receptors undergo endosomal sorting like any other internalized 
membrane protein, then they can be recycled back to the surface membrane or degraded 
in lysosomes (Ehlers 2000; Lin, Ju et al. 2000; Gruenberg 2001). Other studies have 
demonstrated that others pathways of degradation such as the proteasome were not 
involved in the reduction of the AMPA receptor protein level (Lee, Simonetta et al. 
2004). A depletion of AMPA receptors by lysosomal degradation would decrease the 
size of the AMPA receptor pool available for cycling and activity-dependent 
reinsertion, which in turn would lead to reduced levels of synaptic AMPA receptors. 
Furthermore, it was demonstrated that GluR2 rapidly recycles back to the surface after 
endocytosis, and thus the intracellular accumulation level of GluR2 quickly reaches 
steady state at a low value (Lee, Simonetta et al. 2004). This suggests a predisposition 
to fill quickly a temporary gap of receptors in the membrane.
Several evidences such as ubiquitinated inclusions described in ALS patients (Bendotti, 
Atzori et al. 2004) and transgenic mice (Cheroni, Peviani et al. 2005) have suggested an 
abnormal proteolysis in the motor neuron degeneration of ALS which involved the 
ubiquitin proteasome system. However, other proteolytic pathways, such as endosome- 
lysosome system may be altered. Recently, proteomics studies in SOD1G93A mouse
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spinal cord have shown increase in proteins associated with lysosomes (Lukas, Luo et 
al. 2006). These evidences suggest an altered mechanism of protein degradation by the 
lysosome that could alter the level of GluR2 subunit in the cytosol. Interestingly, 
internalized GluR2, but not other subunits, is sorted to endosomes-lysosomes in 
response to NMDA stimulation, suggesting that an overall glutamate receptor stimulus 
can contribute to increase the degradation of this subunit (Lee, Simonetta et al. 2004). 
This in turn could alter the finely regulated mechanisms of the intracellular trafficking 
of this protein leading to motor neurons being highly susceptible to glutamatergic 
stimulus. Further studies are necessary to confirm this hypothesis such as experiments 
of live imaging in SOD1 mutated culture cells to study the dynamic events that regulate 
the trafficking of this subunit between the membrane and the endosome/lysosome.
In addition, in this part of the thesis it has been analyzed the phosphorylated status of 
the GluR2 subunit with an antibody selectively directed to phosphorylated serine site 
880. The phosphorylated protein is only present in the membrane as shown by the 
immunoband found exclusively in the LP1 fraction in western blot. This partially agrees 
with the higher immunofluorescence found near the motor neuron membrane in respect 
to the cytosol. However, no changes were detected in the motor neurons between the 
SOD1G93A mice at the presymptomatic stage and their non transgenic littermates. The 
phosphorylation status of the AMPA receptors is associated to a post-translational 
mechanism aimed to promote the internalisation of the GluR subunits into the cytosol in 
such way to mantain an uninterrupted recycling of these proteins between the cytosol 
and the postsynaptic membrane (Esteban, Shi et al. 2003; Boehm and Malinow 2005). 
Several kinases which are capable to finely regulate the surface expression and
trafficking of the AMPA receptor subunits were described to interact post
2+transcriptionally with GluR2; among them, the most important is PKC, a Ca 
dependent enzyme (McDonald, Chung et al. 2001). There are evidences that the activity
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of PKC is substantially increased in tissue from ALS patients, suggesting that 
alterations in intracellular free Ca2+ may be responsible for the increased activation also 
of this enzyme. An increased expression of PKC was reported in the spinal cord of ALS 
mouse model (Hu, Chemoff et al. 2003; Dave, Raval et al. 2005). Considering that the 
levels of the GluR2 subunits were found to be decreased in the cytosol and no 
phosphorylated protein was found in this compartment, I can not exclude that the 
increased activity of PKC might contribute to an increased internalisation of the protein 
favouring its pathway toward the degradation.
It is quite well established that motor neurons are more susceptible than other spinal 
neurons to toxicity mediated by AMPA receptors. It has been hypothesized that this 
selective vulnerability might result from differences in AMPA receptor subunit 
expression. For example, the presence of AMPA receptors lacking GluR2 or lacking 
edited GluR2 would confer an increased Ca2+ permeability, which in turn can lead to 
deleterious enhanced levels of intracellular calcium and cell death. Therefore, the 
decreased level of GluR2 showed in this study may be the cause of changes in 
homeostasis of the calcium in the motor neurons. The most important subcellular 
organelle able to store limited amount of calcium is the mitochondria. A series of
evidences suggest a tight relation between altered glutamatergic stimulus and
2_|_
mitochondria dysfunction. An increased influx of calcium through Ca AMPA 
permeable receptors induces a selective damage of the mitochondria in motor neurons 
(Carriedo, Sensi et al. 2000). On the other hand glutamate receptor alteration could be 
secondary to mitochondrial dysfunction induced by other factors such as the 
accumulation of mutant SOD1 (Liu, Lillo et al. 2004). In fact, a study carried out on 
mixed spinal cord cultures derived from the SOD1G93A transgenic mice showed an 
increased vulnerability of motor neurons to AMPA mediated glutamate toxicity 
(Spalloni, Albo et al. 2004). This was associated with enhanced reactive oxygen species
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production, sustained elevations of intracellular calcium levels, and mitochondrial 
dysfunction (Kruman, Pedersen et al. 1999). In this respect, it is noteworthy that one of 
the earliest alteration in SOD1G93A mice is the vacuolization of mitochondria in motor 
neurons (Bendotti, Calvaresi et al. 2001).
However, other studies carried out on another model carrying G86R mutation in murine 
SOD1 did not find apparent changes in GluR2 immunostaining in spinal cord of these 
mice at both presymptomatic and symptomatic stage of the pathology (Morrison, 
Janssen et al. 1998). These mice develop an aggressive disease and only few days pass 
between the onset of symptoms and total immobility and death (Ripps, Huntley et al. 
1995). This rapid development of the pathology, so different from the disease 
progression occurring in ALS patients and in SOD1G93A mice, renders this model 
quite different from the chronic course of the human illness.
With the progression of the disease, an increased reactive gliosis occurs in the spinal 
cord that becomes prominent at the end stage. I observed that GluRl, but not the other 
subunits, increased their expression in reactive astrocytes, while the GluR2 and 3 
subunits become prominently expressed in microglia.
There is increasing evidence that functional glutamate receptors are not restricted to 
neurons, but also expressed in glial cells (Biber, Laurie et al. 1999; Noda, Nakanishi et 
al. 2000; Hirayama and Kuriyama 2001; Nakamura 2002; Taylor, Diemel et al. 2003; 
Hagino, Kariura et al. 2004; Christensen, Ha et al. 2006). Microglial cells are rapidly 
activated in response to even minor pathological changes so that they may be viewed as 
the cellular sensory element of brain pathology (Kreutzberg 1996). Moreover, microglia 
is known to be activated in glutamate receptor agonist-induced lesions, as demonstrated 
in hippocampal slice preparations where KA-induced neuronal excitotoxicity is 
associated with dose-dependent activation of glial cells (Akiyama, Tooyama et al. 1994; 
Abraham, Losonczy et al. 2001). Furthermore, neuronal death with a consequent release
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of toxic factors can lead to the activation of microglia that in turn may exacerbate 
neuronal excitotoxicity (Moriguchi, Mizoguchi et al. 2003; Siao, Fernandez et al. 2003). 
The mechanisms underlying the upregulation of GluRs in reactive glial cells revealed in 
SOD1G93A mice is unknown. However, it has been shown that AMPA receptor 
stimulation mediates cytoskeletal alterations in microglia leading the cells from a 
resting to an activated state (Christensen, Ha et al. 2006). Other evidences have reported 
an altered expression of AMPA receptor subunits in the glial cells after excitotoxic 
stimulus which was associated with an enhancement of cytokines production and 
among them particularly increased was TNFa (Gottlieb and Matute 1997; Pellegrini- 
Giampietro, Gorter et al. 1997; Noda, Nakanishi et al. 2000; Hagino, Kariura et al. 
2004). This is of particular interest given that the levels of this cytokine have been 
revealed to be augmented in the transgenic mice (Hensley, Floyd et al. 2002; Yoshihara, 
Ishigaki et al. 2002; Hensley, Fedynyshyn et al. 2003) and in CSF of ALS patients 
(Poloni, Facchetti et al. 2000). This suggests a possible relation between 
neuroinflammation and excitotoxic stimulus leading to synergic deleterious effect on 
the motor neurons.
Noteworthy, it has been demonstrated that the expression within motor neurons of 
mutated human SOD1 is the primary determinant of the disease onset of the transgenic 
mice, whereas diminishing selectively the mutant human SOD1 in the microglia has 
little effect on the early disease phase but sharply slowed later disease progression 
(Boillee, Yamanaka et al. 2006). This demonstrates a no cell autonomous mechanism in 
the developing of the disease and an important role during the progression of the disease 
could be ascribed to the activation of the microglial cells. Taken together, these results 
suggest that the activation of the microglia may initiate or contribute to motor neurons 
death by increasing their susceptibility to the toxic effects of glutamate.
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CHAPTER 4
Study of the expression of glutamate AMPA 
receptor trafficking proteins in the spinal 
cord of SOD1G93A mice during the 
progression of the disease
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4.1 EXPRESSION AND DISTRIBUTION OF AMPA 
RECEPTOR TRAFFICKING PROTEINS IN THE 
SPINAL CORD OF SOD1G93A MICE DURING THE 
PROGRESSION OF THE DISEASE EXAMINED BY 
IMMUNOFLUORESCENCE ANALYSIS AND 
BIOCHEMISTRY
4.1.1 HYPOTHESIS AND AIM
The previous results have shown a decrease of GluR2 in the motor neurons and 
particularly in the cytosol subfraction of ventral spinal cord from SOD1G93A 
mice at the presymptomatic stage, suggesting an alteration in the trafficking of 
these receptors.
Hence, I have examined whether changes in the expression and distribution of 
AMPA receptor trafficking proteins (ABP, PICK1 and NSF) occurs in motor 
neurons of SOD1G93A. Deregulation of AMPA receptors trafficking may 
influence the GluR subunits stoichiometry in the post synaptic membrane 
predisposing motor neurons to an uncontrolled influx of ions in the cytoplasm 
and altering the mechanism that regulate this homeostasis, leading to 
excitotoxicity.
I examined by immunofluorescence the protein expression of three important 
proteins involved in AMPA subunit trafficking (ABP, PICK1 and NSF) in 
lumbar spinal cord of SOD1G93A mice during the progression of disease in
respect to their non transgenic littermate. Moreover, I evaluated the levels and 
distribution of the AMPA receptor trafficking proteins in total homogenate and 
in subcellular fractions from lumbar spinal cord of SOD1G93A and non 
transgenic mice.
4.1.2 RESULTS
4.1.2.1 STUDY OF EXPRESSION OF GLUTAMATE AMPA RECEPTOR 
TRAFFICKING PROTEINS IN THE SPINAL CORD OF SOD1G93A 
MICE BY IMMUNOFLUORESCENCE
ABP staining:
In the spinal cord sections of control non transgenic mice, ABP resulted 
predominantly distributed in the motor neurons stained by FG and in the 
substantia gelatinosa (Fig 4, A; a,b). At high magnification a clear staining was 
revealed in the perikarya and in the dendrites of the motor neurons, including 
the distal part of the arborisation which was not stained by the FG (Fig 4, A; 
c,d). In transgenic mice at the presymptomatic (Fig 4, A; g,h arrow), 
symptomatic (Fig 4.1; c,d) and end stage (Fig 4.2, A; c,d) of the disease, I have 
not detected clear changes in ABP expression and distribution compared to 
control mice at the same age, except for a decreased staining in some vacuolized 
motor neurons (Fig 4, A; g,h arrow).
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PICK1 staining:
In control mice PICK1 was mostly localized in the perykaria of the motor 
neurons and at lower level in the substantia gelatinosa (Fig 4, B; a,c). In 
SOD1G93A mice, this labelling increased diffusely in the perikarya of the 
neurons of the ventral hom and particularly in the motor neurons as shown by 
the increase colocalization signal of PICK1 with the FG at the presymptomatic 
stage (Fig 4 B; e-h). However, an increase signal was detected also in the dorsal 
hom of transgenic mice compared to control mice, at all stage of the disease 
examined (Fig 4 B; e-h , Fig 4.1, e-h, arrows , Fig 4.2 A; e-h). PICK1 was not 
found in reactive glial cells of SOD1G93A mice at the symptomatic and end 
stage (Fig 4.1, e-h, arrows, Fig 4.2 A; e-h).
NSF staining:
Analyzing NSF in control mice, I have revealed a labelling localized mostly in 
the perikarya of the motor neurons stained by FG (Fig 4, C; a,c). This labelling 
was increased selectively in the motor neuron cells as shown by an increase 
colocalization signal between NSF and FG at the presemptomatic stage (Fig 4 
C; e-h), but also at symptomatic and end stage of the disease of the transgenic 
mice (Fig 4.1, i-1, arrows, Fig 4.2 A; i-1), whereas, I did not detect differences in 
the dorsal hom of the transgenic mice (Fig 4 C; e ,g , Fig 4.1, i,k , Fig 4.2 A; i,l). 
Furthermore, when I analyzed the distribution at the end stage of the disease, I 
detected a scattering signal exclusively for NSF that colocalized with some 
GFAP positive reactive astrocytes (Fig 4.2 B;h, arrows).
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Fig 4: ABP, PICK1 and NSF immunofluorescence in lumbar spinal cord of
SOD1G93A mice at the presymptomatic stage of the disease
At the presymptomatic stage o f the disease, a marked immunoreactivity fo r ABP, 
PICK1 and NSF (red) is localized mostly in the motor neurons o f ventral hom and in 
dorsal hom (A,B,C; a,c). In the motor neurons, stained by Fluorogold (FG, green), 
immunostaining for ABP is distributed in the perikarya and neurites (A; a,c), whereas 
both PICK1 and NSF are localized mostly in the cytosol o f the motor neurons (B,C; 
a,c). No differences for ABP immimostaining are observed in the ventral and dorsal 
hom o f SOD1G93A mice (A; a,e,c,g). Whereas, an increased labelling appears in the 
ventral region for both PICK1 and NSF (B,C; a,e,c,g), and also in dorsal region for 
PICK1 (B; a,e). In particular, we observed an increase o f PICK1 and NSF 
immunostaining in the perikarya o f motor neurons in the ventral hom (B,C; g). Scale 
bars: (A,B,C; a,b,ef=  200 pm); (A,C; c,d,g,h= 50 pm).
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Fig 4.1: ABP, PICK1 and NSF immunofluorescence in lumbar spinal cord 
of SOD1G93A mice at the symptomatic stage of the disease
At the symptomatic stage o f the disease, an increased immunoreactivity fo r both PICK1 
and NSF (red) is showed in the motor neurons o f ventral horn o f SOD1G93A mice (h,l 
arrows), and in dorsal horn for PICK1 (g) compared to control mice (e,fi,j). No 
differences for ABP immunostaining are observed in the ventral and dorsal horn o f  
SOD1G93A mice (a-d). Scale bars: (a,c,e,g,i,k = 200 pm); ( b,d,fh,j,l= 50 pm)
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Fig 4.2: ABP, PICK1 and NSF immunofluorescence in lumbar spinal cord
of SOD1G93A mice at the end stage of the disease
At the endstage o f the disease, again an increased immunoreactivity fo r both PICK1 
and NSF (red) is shown in the motor neurons o f ventral hom o f SOD1G93A mice (A; 
h,l) and in the dorsal hom fo r PICK1 (A, g), compared to control mice (A; fj) . 
Whereas, no differences for ABP immunostaining are observed in the ventral and 
dorsal hom o f SOD1G93A mice (A; a-d). Furthermore, an increased scattering signal 
fo r NSF is revealed at this stage o f the disease in the ventral hom o f transgenic mice 
that colocalize with astrocytes showed in green (B; g,h, arrows )  Scale bars: 
(A;a,c,e,g,i,k =  200 pm); (A;b,df,h,j,l= 50 pm); (B;a,b,c,d = 200 pm); (B;ef,g,h,= 50 
pm)
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4.1.2.2 STUDY OF SUBCELLULAR DISTRIBUTION OF GLUTAMATE 
AMPA RECEPTOR TRAFFICKING PROTEINS IN THE SPINAL 
CORD OF SOD1G93A MICE BY BIOCHEMISTRY
The protein expression of AMPA receptor trafficking proteins ABP, PICK1 and 
NSF was investigated in the ventral and dorsal portion of the lumbar spinal cord 
of ALS transgenic mice at the presymptomatic stage in respect to age matched 
non transgenic mice. Tissues were obtained as total homogenate with the 
procedure described in section 2.3.1.1 or fractionated as described above in 
section 2.3.1.2. Two fractions were analyzed, a cytosol fraction, P3, and a 
synaptosomal membrane enriched fraction, LP1. The quantitative evaluation of 
the bands was carried out as described in section 2.3.1.3.
ABP protein:
The amount of ABP protein expressed in the ventral and dorsal spinal cord of 
SOD1G93A mice was tested at the presymptomatic stage. Analyzing the total 
homogenate and the two fractions, LP1 and P3, a detectable signal of ~80 KDa 
for ABP was revealed (Fig 4.3 A, 4.4A)
A quantitative determination of the band optical density for the immunoblot on 
total homogenate has shown no differences between control and transgenic mice 
at the presymptomatic stage of the disease (Fig 4.3A). Similarly, no differences 
were found for LP1 and P3 fraction (Fig 4.4A). However, a p value for the LP1 
fraction of P=0.16 close the significance has been detected.
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PICK1 protein:
PICK1 showed a band of -50 KDa in the total homogenate and in the 
subcellular fractionation of the ventral and dorsal spinal cord of SOD1G93A 
mice.
A quantitative determination of the band optical density has shown no 
differences in the total homogenate between control and transgenic mice at the 
presymptomatic stage (Fig 4.3B).
Analyzing the two fractions, LP1 and P3, only a detectable signal for PICK1 has 
been revealed in cytosolic fraction P3, which was not different from that found 
in the control mice (Fig 4.4B).
NSF protein:
The evaluation of NSF protein level expressed in the ventral and dorsal spinal 
cord of SOD1G93A mice revealed a -75 KDa band in the total homogenate and 
in the two fractions analyzed (Fig 4.3C, 4.4D). A quantitative determination of 
the band optical density has shown no differences between control and 
transgenic mice at the presymptomatic stage of the disease for the total 
homogenate (Fig 4.3C). Interestingly, analyzing the two fractions LP1 and P3 at 
the presymptomatic stage no differences were found for the synaptosomal 
membrane enriched fraction LP1, whereas a significant increase was revealed 
for the cytosolic fraction P3 of transgenic mice compared to controls (Fig 4.4D).
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Fig 4.3: Western blot analysis of the expression of AMPA trafficking 
proteins in total homogenate of ventral and dorsal spinal cord of 
SOD1G93A mice
Lack o f differences in ABP, PICK1 and NSF band intensity were observed in 
SOD1G93A mice at presymptomatic stage o f the disease compared to controls at the 
same age (A,B,C). The graphics show quantitative evaluation o f ABP, PICK1 and NSF 
(A,B,C) protein levels expressed as ratio between their band intensity and actin band 
intensity from the same blot (D). Each column shows the mean ±S.E .M  (n=7). Data 
analysed by Mann Whitney test.
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Fig 4.4: Western blot analysis of the expression of AMPA receptor subunits 
in subcellular fractionation of ventral and dorsal spinal cord of SOD1G93A 
mice
No evident differences in ABP and PICK1 band intensity, the latter revealed only in P3 
fraction, were observed in SOD1G93A mice at the presymptomatic stage o f  the disease 
when compared to controls at the same age (A,B). A significant increase in NSF band
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intensity was only found in the P3 fraction of transgenic mice compared to control (D). 
Graphics show quantitative evaluation of ABP,PICK1, NSF (A,C,D) protein levels 
expressed as ratio between their band intensity and PSD95 band intensity from the 
same blot for the LP1 fraction (B), whereas as ratio with GM130 for the P3 fraction 
(C). Each column shows the mean ± S.E.M (n=7). Data analysed by Mann Whitney 
test.
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4.2 DISCUSSION
The most important role of AMPA receptors is to mediate fast excitatory 
synaptic transmission in the nervous system. Changes in the responsiveness of 
postsynaptic AMPA receptors can regulate excitatory synaptic transmission. A 
possible mechanism underlying the modification of AMPA receptor activity is 
the change in the number of AMPA receptors in the postsynaptic membrane. In 
fact, it has been suggested that altering the trafficking of AMPA receptors to 
postsynaptic membrane leads to alterations in synaptic efficacy and that the 
prolonged activation is potently neurotoxic (Lissin, Gomperts et al. 1998; 
Luscher, Xia et al. 1999; Shi, Hayashi et al. 1999; Lin, Ju et al. 2000; Luscher, 
Nicoll et al. 2000; Man, Lin et al. 2000; Turrigiano 2000; Wang and Linden 
2000; Carroll, Beattie et al. 2001). In the neurons, AMPA receptors are 
clustered at postsynaptic sites (Craig, Blackstone et al. 1993; Molnar, Baude et 
al. 1993) with a significant proportion in the cytosol (Petralia and Wenthold 
1992; Martin, Blackstone et al. 1993; Molnar, Baude et al. 1993; Henley 1995; 
Hall and Soderling 1997). Changing the surface expression of AMPA receptors 
can result from a bidirectional rapid translocation from and to the intracellular 
pool. A tight cellular regulation of the trafficking of these receptors for a 
functional synaptic expression was characterized and associated with several 
cytoplasmic proteins such as GRIP/ABP, PICK1 and NSF (Dong, O'Brien et al. 
1997; Kennedy 1997; Ziff 1997; Nishimune, Isaac et al. 1998; Osten, Srivastava 
et al. 1998; Song, Kamboj et al. 1998; Srivastava, Osten et al. 1998; Li, 
Kerchner et al. 1999; Noel, Ralph et al. 1999; Wyszynski, Valtschanoff et al. 
1999; Xia, Zhang et al. 1999; Man, Lin et al. 2000). They are involved in the 
regulation of post translational modification, targeting, trafficking, surface
expression and anchoring of AMPA receptors. In this part of the thesis the 
distribution and expression of these three important proteins was tested. The 
main findings of this study are the changes found for PICK1 and NSF. A diffuse 
increased staining in the neurons of the grey matter was detected already at the 
presymptomatic stage of the disease for PICK1 in the lumbar spinal cord of the 
transgenic mice, which persists during the progression of the disease in the 
remaining neuronal cells. Whereas a selective increase staining in the motor 
neuron cells was found for NSF at presymptomatic stage of the disease and 
persist in the remaining motor neurons during the progression of the disease. 
However, analyzing the total homogenate and the subcellular fractions of 
ventral and dorsal horn at the presymptomatic stage, no changes for PICK1 
were revealed in P3 fraction. Whereas, no reveable signal was obtained in LP1 
fraction, this in line with other studies showing the localization of PICK1 in 
perinuclear region, rough endoplasmic reticulum and Golgi apparatus 
(Staudinger, Zhou et al. 1995). This result is at variance with the 
immunofluorescence at the same stage; this is likely due to the sensitivity of this 
technique that is not able to reveal augmented level of this specific protein in a 
small portion of cells such as showed by immunofluorescence.
In contrast, a significantly increased level of NSF protein was found in the 
cytosolic fraction P3 of the transgenic mice, whereas no difference was revealed 
in the synaptosomal membrane fraction LP1.
Different roles were associated with these proteins. For PICK1, it was 
hypothesized that two mechanisms are involved in the trafficking of the AMPA 
subunits: the first suggests that the AMPA phosphorylation by kinases causes 
the recruitment of PICK1 to the synaptic AMPA subunits and then PICK1 
promotes the internalization of AMPA subunit by clathrin-mediated
endocytosis. Alternatively, PICK1 can binds the AMPA receptors in the internal 
pool, stabilizing them and attenuating compensatory AMPA receptor insertion 
in the membrane (Xia, Chung et al. 2000).
NSF is involved in the disruption of multiprotein complexes with the AMPA 
receptor, such as those formed between the proteins of the postsynaptic density 
(Hanley, Khatri et al. 2002). In fact, it has been demonstrated that NSF regulates 
selectively the interaction between GluR2 and PICK1, disassembling PICK1- 
GluR2 complexes, resulting in an increased translocation of AMPA receptors to 
the cell surface (Hanley, Khatri et al. 2002). These suggest an opposite role for 
PICK1 and NSF in the finely regulated distribution of the AMPA receptor 
subunits between the postsynaptic membrane and the cytosol. Interestingly, 
NSF binds selectively GluR2, but not others subunits (Nishimune, Isaac et al. 
1998; Beretta, Sala et al. 2005). Furthermore, NSF inhibits the targeting of 
GluR2 to lysosomes by promoting recycling of internalized GluR2 to the 
membrane. This hypothesis is supported by experiments showing that the lack 
of NSF is able to increase the sorting of GluR2 to the endosomes (Lee, 
Simonetta et al. 2004).
It is possible to speculate that the diffuse specific increase level of PICK1 in 
neurons of the transgenic mice may represent an epiphenomenon not related to 
the selective motor neuron degeneration. Furthermore, a lack of increased 
phosphorylation of the GluR2, which precedes the internalization of this subunit 
and the binding with PICK1, seems to suggest a non-determinant role of this 
protein in the regulation of the trafficking of GluR2 subunit during the 
progression of the disease. Instead, noteworthy is the specific increase level of 
NSF in the cytosol of the motor neurons, which may be considered an attempt to
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counteract the altered degradation of GluR2 subunit and to stabilizing the steady 
state level of GluR2 in the membrane.
Another interesting result was the increased expression of NSF in the 
hypertrophic astrocyte cells at the end stage of the disease of transgenic mice. 
So far, in the literature this protein was characterized in neurones (Nishimune, 
Isaac et al. 1998; Osten, Srivastava et al. 1998; Song, Kamboj et al. 1998; Noel, 
Ralph et al. 1999; Hanley, Khatri et al. 2002; Beretta, Sala et al. 2005) without 
any detailed analysis in the glial cells. This is the first evidence of the presence 
of NSF in glial cells in a pathologic environment. Other studies are necessary to 
explain what is the role of this alteration in this pathology.
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CHAPTER 5 
GENERAL DISCUSSION
Amyotrophic lateral sclerosis is the most common form of motor neuron 
disease. There is not a cure or treatment today that halts or reverses this 
pathology. Studies carried out on post mortem human tissues and mouse models 
of ALS have revealed the involvement of a large number of different 
intracellular pathways and alteration of several biochemical systems in motor 
neurons and surrounding glial cells. Even so, the general picture of the disease 
and of its pathogenesis still results uncertain, since almost every alteration 
found can be the consequence or cause of the others. Relevant in order to 
understand the disease mechanism and development of treatments are the early 
events that characterize this pathology. An important breakthrough occurred 
with the discovery of mutations in the gene SOD1 as a primary cause of some 
forms of familial ALS. Since this relevant discovery, in vitro and in vivo models 
were developed and have helped us to begin understanding mechanisms 
involved in motor neuron death at the early stage of the disease and allowed us 
to test potential new therapies. Among the different model, the most used is the 
transgenic mice expressing some of the SOD1 mutants discovered in ALS 
patients, which display symptoms and neuropathological features that closely 
resemble the human disorder.
ALS clinical symptoms and neuropathological characteristics showed by 
patients affected by familial ALS are very similar to those occurring in sporadic 
case of the disease. This suggests that selective motor neuron death can be 
triggered by different events that, however, lead to a common intracellular 
pathway of death. Thus, the comprehension of the death processes that lead to 
the pathology in FALS mice will also be useful to the treatment of sporadic 
form of ALS.
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To date, only one drug is approved by FDA for ALS, Rilutek® (Riluzole), 
which is able to slow down the progression of ALS, but with a modest effect. 
This drug has been demonstrated to be able to interact with the glutamatergic 
stimulus. This suggests that an excitotoxic event could represent a crucial point 
in the developing of the disease.
In this study, I have used the SOD1G93A transgenic mice to investigate the role 
of excitotoxicity in the etiopathology of the disease. In particular, I have studied 
possible alterations in the trafficking of the AMPA receptor subunits and the 
main proteins that regulate these dynamic events, considering these alterations 
as a potential trigger or contribution to motor neuron degeneration.
There is substantial evidence that decreased levels of GluR2 generate AMPA 
receptors highly permeable to calcium ions leading to excitotoxic processes 
(Hollmann, Hartley et al. 1991; Hume, Dingledine et al. 1991; Verdoom, 
Bumashev et al. 1991; Bumashev, Zhou et al. 1995; Kuner, Beck et al. 2001). 
The selective AMPA antagonist NBQX showed protective effects on MND 
mice, significantly improving the motor function scores, and on SOD1G93A 
mice, prolonging their survival (Mennini, Cagnotto et al. 1999; Van Damme, 
Leyssen et al. 2003). The same effect on SOD1G93A mice was obtained in a 
study with another AMPA antagonist RPR 119990, which also improved the 
grip muscle strength of these ALS mice (Canton, Bohme et al. 2001). Moreover, 
our group has demonstrated that a new 2,3 benzodiazepine, ZK 187638, which 
displays non competitive AMPA antagonist properties, led to improvement of 
symptoms and a significant prolongation of the life span of SOD1G93A mice 
(Tortarolo, Grignaschi et al. 2006). These promising results indicate that 
blockade of AMPA-mediated glutamatergic stimulus could be an important 
therapeutic target. It is interesting to note that one of the earliest
180
neuropathological features observed in the motor neurons of SOD1G93A mice 
is represented by mitochondrial swelling which is particularly sensitive to 
altered calcium homeostasis (Bendotti, Calvaresi et al. 2001). Furthermore, 
increased vulnerability of motor neurons expressing SOD1G93A to glutamate 
toxicity by AMPA receptors was described in cultured cells (Spalloni, Albo et 
al. 2004).
It is still unclear, however, how the AMPA receptors, and in particular GluR2, 
can be regulated to determine the selective vulnerability of spinal motor 
neurons. A possible abnormality of the mechanisms regulating the bidirectional 
trafficking of the AMPA subunits between the cytoplasm and the postsynaptic 
membrane may represent a new important target that if compromised may lead 
to motor neuron degeneration.
About this topic, reduced levels of GluR2 protein, but not mRNA, have been 
recently documented by our group (Tortarolo, Grignaschi et al. 2006). In this 
thesis, I have extended those results demonstrating that a significant reduced 
levels of GluR2 was present in the cytosol of the motor neurons of the 
transgenic mice (Chapter 3), whereas unchanged levels of the protein was 
revealed in the postsynaptic membrane of transgenic mice when compared to 
control mice. It is possible to speculate that a reduced level of GluR2 is 
associated to increasing degradation activity of lysosomal machinery, the only 
degradation pathway so far characterized for the AMPA receptors. Interestingly, 
an altered lysosomal activity was documented in ALS patients and transgenic 
mice (Kikuchi, Yamada et al. 2003; Lukas, Luo et al. 2006) that could support 
this hyphothesis. Furthermore, it was also demonstrated that an increased 
stimulation of glutamate receptors is able to augment the degradation by 
lysosome of the AMPA receptor subunits (Lee, Simonetta et al. 2004). This
corroborates the evidences in ALS patients of a marked decrease in the 
glutamate uptake in synaptosomes from spinal cord and motor cortex 
(Rothstein, Martin et al. 1992) and a massive loss of EAAT2 immunoreactivity 
in the same areas of the nervous system affected pathologically (Rothstein, Van 
Kammen et al. 1995). Furthermore, western blot analysis of the spinal cord total 
proteins of transgenic mice carrying G85R and G93A SOD1 mutant or 
transgenic rat model mutated in G93A have also shown a decline of GLT-1 
expression (Bruijn, Becher et al. 1997 , Bendotti, Tortarolo et al. 2001, 
Howland, Liu et al. 2002). Taken together these results suggest an increase in 
the level of glutamate in the synaptic cleft available to stimulate glutamate 
receptors.
Despite a lack of change revealed in the postsynaptic membrane in this thesis, 
where the AMPA receptors are functionally active, there are evidences in 
literature that the trafficking of the AMPA receptors between the postsynaptic 
membrane and the cytosol is finely regulated, suggesting that a perturbation of 
this equilibrium can lead to deleterious effects in the glutamatergic stimulus 
(Carroll, Lissin et al. 1999; Luscher, Xia et al. 1999; Beattie, Carroll et al. 2000; 
Ehlers 2000; Lin, Ju et al. 2000; Malinow, Mainen et al. 2000; Man, Lin et al. 
2000; Wang and Linden 2000; Carroll, Beattie et al. 2001).
It is also known that the presence of the Q/R edited form of GluR2 in the 
molecular structure of AMPA receptors determines the calcium impermeability 
of the channel. As outlined in the introduction to this chapter, changes in GluR2 
edited form with an unedited form in the motor neurons can results in increased 
calcium permeability of AMPA receptors and might lead to pathological 
condition in ALS, determining or contributing to motor neuron degeneration. 
Furthermore, it was demonstrated that the unedited form at the Q/R site is much
more efficiently transferred to the membrane than the edited form (Greger, 
Khatri et al. 2002; Greger, Khatri et al. 2003). For instance, the efficiency of 
this editing is significantly reduced in the spinal ventral grey matter of 
individuals with ALS compared to control groups (Takuma, Kwak et al. 1999; 
Kawahara, Ito et al. 2004). However, these data were not confirmed by other 
groups and in a rat model of ALS carrying mSODl, the GluR2 mRNA was 
completely edited in motor neurons. Other indications of a deregulated 
trafficking of the AMPA receptor revealed in my thesis were the increased 
expression of NSF in concomitance with the GluR2 downregulation in the 
motor neurons of transgenic mice. Increasing level of NSF correlates with an 
increased delivery of AMPA receptors at the cell surface. Hence, it is possible 
to suppose that an increase level of this protein is an attempt to stabilize the 
GluR2 subunit in the membrane as a consequence of a decrease availability of 
GluR2 in the cytosol of the motor neurons. Again, NSF seems to inhibit also the 
targeting to lysosomes by promoting recycling of internalized GluR2 to the 
membrane (Lee, Simonetta et al. 2004), increasing in strength the hypothesis of 
an attempt to stabilize a pathologic condition.
Abnormal Ca influx through AMPA receptors in neurons can also determine 
activation of stress pathways, which in turn, may contribute to activation of 
death processes. Among them, one of the most important is linked to the 
p38MAPK, a mitogen activated kinase, which our group demonstrated to be 
activated (phosphorylated) in SOD1G93A mice (Tortarolo, Veglianese et al. 
2003). On the other hand, the action of phosphorylated p38MAPK was also 
correlated to altering the AMPA receptor composition. In fact, it has been 
demonstrated that damage processes can be mediated by AMPA receptors 
through p38MAPK signalling after an excessive Ca2+influx through glutamate
receptors (Rivera-Cervantes, Torres et al. 2004; Torres, Chaparro-Huerta et al. 
2006).
With the progression of the disease, a massive activation of glial cells, both 
astrocytes and microglia, occur in the ventral horn of lumbar spinal cord of 
SOD1G93A mice. The results reported in this thesis showed that GluRl, 2 and 
3 expression is remarkably increased also in the glial cells during the 
progression of the pathology (Chapter 3). So far, the mechanism underlying the 
upregulation of GluR in reactive glial cells revealed in SOD1G93A mice is not 
completely known. However, it was reported that an altered expression of 
AMPA receptor subunits occurs in glial cells after an excitotoxic stimulus 
which was associated with an enhancement of production of cytokines such as 
TNFa (Gottlieb and Matute 1997; Pellegrini-Giampietro, Gorter et al. 1997; 
Noda, Nakanishi et al. 2000; Hagino, Kariura et al. 2004). This may account for 
increase levels of this cytokine in the transgenic mice (Hensley, Floyd et al. 
2002; Yoshihara, Ishigaki et al. 2002; Hensley, Fedynyshyn et al. 2003) and in 
CSF of ALS patients (Poloni, Facchetti et al. 2000). Furthermore, published 
results obtained in our laboratory showed that TNFa receptors are over 
expressed in the motor neurons of presymptomatic stage and in the microglial 
cells during the progression of the disease in SOD1G93A mice (Veglianese et 
al. 2006).
In addition, inhibition of AMPA receptors by CNQX antagonist prevented the 
toxic effects on the motor neurons of activated microglia stimulated by 
lipopolysaccharide or IgG immune complexes from patients with ALS (Zhao et 
al. 2004), suggesting once again a link between excitotoxicity and 
neuroinflammation.
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In conclusion, this study demonstrates an altered composition of glutamate 
AMPA receptors in motor neurons of SOD1G93A mice. In particular, decreased 
levels of GluR2 in the motor neurons may increase the susceptibility of these 
cells to the physiologic glutamate stimulus. Since the lack of GluR2 was 
observed mostly in the cytosol, this indicates an altered trafficking of the 
receptor subunit which might be due to an increased degradation of the protein 
by the lysosomal pathway. Interestingly, we observed in the motor neurons at 
the presymptomatic stage an increase level of NSF, whose activation results in 
augmented delivery of AMPA at the membrane. So, the increase of NSF could 
be an attempt to stabilize the remaining GluR2 AMPA receptor at the 
membrane (Fig 5.1).
Furthermore, the vulnerability of these neurons, in respect to glutamate-induced 
degeneration, is likely exacerbated by increased expression of GluR subunits in 
the glial cells during the progression of the disease. These cells might be able to 
release factors that are toxic for the motor neuron cells.
Ongoing experiments: to confirm the relevant role of these proteins in 
transgenic mice, a treatment with antagonist peptide that interferes with the 
interaction of NSF in C-terminal sequence of GluR2 in vivo could represent a 
good possibility to define the role of these proteins in ALS, and as therapeutic 
targets to develop potential drugs for ALS patients.
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Fig 5.1: Cartoon of the results obtained
NSF protein increase in the cytosol (red arrow) 
GluR2 protein decrease in the cytosol (green arrow)
The hope is that the results obtained in this study may contribute to the 
development of future new therapeutic strategies, which can help people 
affected by this devastating pathology.
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